{
    "id": 12444,
    "title": "Vejledning om sikkerhedsvurdering af kosmetiske produkter",
    "documentTypeId": "180",
    "isSagsforlobPeriodValid": true,
    "shortName": "VEJ nr 9474 af 01/01/2000",
    "documentHtml": "<div class=\"bjelke\">Oversigt (indholdsfortegnelse)</div><DIV CLASS=PARA ID=\"OVERSIGT\"> \r\n\r\n\r\n\r\n<UL>  \r\n\r\n</UL>  \r\n\r\n</UL>  \r\n\r\n</UL>  \r\n\r\n<table border=\"0\"><tr><td valign=\"top\" width=\"130\"><A HREF=\"#B1\">Bilag  \r\n\r\n 1</A></td><td></td></table>  \r\n\r\n<table border=\"0\"><tr><td valign=\"top\" width=\"130\"><A HREF=\"#B2\">Bilag  \r\n\r\n 2</A></td><td></td></table>  \r\n\r\n<table border=\"0\"><tr><td valign=\"top\" width=\"130\"><A HREF=\"#B3\">Bilag  \r\n\r\n 3</A></td><td></td></table>  \r\n\r\n</DIV><div class=\"bjelke\">Den fulde tekst</div><DIV CLASS=PARA ID=\"INDHOLD\"> \r\n\r\n\r\n<FONT SIZE=5><P ALIGN=\"CENTER\">Vejledning om sikkerhedsvurdering af  \r\n\r\n kosmetiske produkter</P>  \r\n\r\n</FONT>  \r\n\r\n<P>&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1. Indledning</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    1.1 Baggrund</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    1.2 Lovgivning</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    1.3 Udformning og fremsendelse af oplysninger</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2. Krav til produktoplysninger/dossier</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.1 Produktets sammens&aelig;tning</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.2 Fysisk/kemiske og mikrobiologiske  \r\n\r\n specifikationer</P><DIR>  \r\n\r\n<P>           2.2.1 Generelt</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.2.2 Fysisk/kemiske specifikationer for  \r\n\r\n r&aring;varerne</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.2.3 Kriterier for fysisk/kemisk renhed af  \r\n\r\n r&aring;varerne</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.2.4 Fysisk/kemiske specifikationer for det  \r\n\r\n f&aelig;rdige produkt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.2.5 Fysisk/kemisk renhed af det f&aelig;rdige  \r\n\r\n produkt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.2.6 Mikrobiologisk kontrol af r&aring;varerne og  \r\n\r\n det f&aelig;rdige kosmetiske produkt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.3 Fabrikationsmetoden</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.3.1 Generelt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.3.2 L&oslash;nproduktion</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.4 Sikkerhedsevaluering af det f&aelig;rdige  \r\n\r\n produkt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.4.1 Generelt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.4.2 Den generelle toksikologiske profil</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.4.3 Stoffets kemiske struktur</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.4.4 Evaluering af sikkerheden</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.5 Uddannelseskrav for den/de ansvarlige for  \r\n\r\n sikkerhedsevalueringen</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.6 U&oslash;nskede virkninger for menneskers  \r\n\r\n sundhed</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.6.1 Generelt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.6.2 Registrering</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">    2.7 Bevis for p&aring;st&aring;ede virkninger</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.7.1 Generelt</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">        2.7.2 Principper</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Referenceliste</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Bilag 1</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Bilag 2</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Bilag 3</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138663\">1 Indledning</A></P>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Form&aring;let med denne vejledning er at beskrive, hvad  \r\n\r\n myndighederne forventer med hensyn til omfang og detaljeringsgrad af  \r\n\r\n oplysninger for kosmetiske produkter. Oplysningerne skal endvidere v&aelig;re  \r\n\r\n nemt tilg&aelig;ngelige. Samtidig gives der et forslag til en praktisk  \r\n\r\n fremgangsm&aring;de til indhentning og udarbejdelse af  \r\n\r\n<B>produktoplysninger/dossier </B>for de enkelte produkter, og der anvises  \r\n\r\n anvendelig litteratur hertil. Vejledningen skal dermed v&aelig;re en  \r\n\r\n hj&aelig;lp til, at udarbejdelse af kosmetikdossier sker ensartet hos de  \r\n\r\n enkelte producent er.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">N&aelig;rv&aelig;rende vejledning er udarbejdet for  \r\n\r\n Milj&oslash;styrelsen af Jette Rud Larsen, Dansk Toksikologi Center.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Projektet blev fulgt af en styregruppe, som har givet  \r\n\r\n gode, konstruktive bidrag. Styregruppen bestod af:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Anette Espersen, Forbrugerr&aring;det indtil efter&aring;r  \r\n\r\n 1998</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Heidi S&oslash;sted Rask, Forbrugerr&aring;det fra  \r\n\r\n efter&aring;r 1998</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Liselotte Damgaard, Persano Cosmetics A/S</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Henning Gjelstrup Kristensen, Danmarks Farmaceutiske  \r\n\r\n H&oslash;jskole</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Lars V&aelig;lds Frederiksen, A/S Rosco</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">S&oslash;ren Ebbeskov, Brancheforeningen SPT</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Lisbet &Oslash;lgaard, Milj&oslash;styrelsen</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Lars F. N&oslash;rgaard, Milj&oslash;styrelsen indtil  \r\n\r\n efter&aring;ret 1999</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I for&aring;ret 2000 blev kapitel 2.7 vedr&oslash;rende  \r\n\r\n bevis for p&aring;st&aring;ede virkninger uddybet n&aelig;rmere og en  \r\n\r\n beskrivelse af den faglige baggrund vedlagt i bilag. Annette Orloff,  \r\n\r\n Milj&oslash;styrelsen var herefter koordinator vor vejledningen.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138664\">1.1  \r\n\r\n Baggrund</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Med udgangspunkt i loven om kemiske stoffer og produkter  \r\n\r\n har Milj&oslash;styrelsen udarbejdet en r&aelig;kke bekendtg&oslash;relser,  \r\n\r\n der har til form&aring;l at forebygge sundhedsfare og milj&oslash;skade i  \r\n\r\n forbindelse med fremstilling, opbevaring, anvendelse og bortskaffelse af  \r\n\r\n kemiske stoffer og produkter. Blandt disse er bekendtg&oslash;relsen om  \r\n\r\n kosmetiske produkter (1), der omfatter markedsf&oslash;ring af kosmetiske  \r\n\r\n produkter. Bekendtg&oslash;relsen er udarbejdet med baggrund i regler fra EU-  \r\n\r\n kosmetikdirektivet fra 1976 med efterf&oslash;lgende &aelig;ndringer og  \r\n\r\n tilpasninger (2). Denne vejledning beskriver de krav, der stilles i § 32 i  \r\n\r\n kosmetikbekendtg&oslash;relsen, der bygger p&aring; kravene i artikel 7a i  \r\n\r\n kosmetikdirektivet.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138665\">1.2  \r\n\r\n Lovgivning</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I § 9 i bekendtg&oslash;relsen om kosmetiske produkter er  \r\n\r\n det fastlagt, at kosmetiske produkter, der markedsf&oslash;res i Det  \r\n\r\n Europ&aelig;iske F&aelig;llesskab (EU), ikke m&aring; v&aelig;re til skade  \r\n\r\n for menneskets sundhed, n&aring;r de anvendes under normale betingelser.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Til dokumentation af sikkerheden ved produkterne skal en  \r\n\r\n r&aelig;kke n&aelig;rmere bestemte oplysninger if&oslash;lge  \r\n\r\n bekendtg&oslash;relsens §32 v&aelig;re tilg&aelig;ngelige for alle kosmetiske  \r\n\r\n produkter, der bringes i handlen indenfor EU. If&oslash;lge  \r\n\r\n bekendtg&oslash;relsen om kosmetiske produkter g&aelig;lder  \r\n\r\n f&oslash;lgende:</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">§ 32. Fabrikanten, hans befuldm&aelig;gtigede, den  \r\n\r\n person, p&aring; hvis bestilling et kosmetisk middel fremstilles eller den  \r\n\r\n ansvarlige for markedsf&oslash;ringen i F&aelig;llesskabet af indf&oslash;rte  \r\n\r\n kosmetiske midler skal sikre, at de kompetente myndigheder i de  \r\n\r\n p&aring;g&aelig;ldende medlemsstater -i Danmark Milj&oslash;styrelsen - har  \r\n\r\n nem adgang til nedenst&aring;ende oplysninger p&aring; den adresse, der er  \r\n\r\n anf&oslash;rt p&aring; etiketten i overensstemmelse med § 17.</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Oplysningerne, der kr&aelig;ves er omtalt i et teknisk  \r\n\r\n vejledningsdokument fra EU s videnskabelige komit&eacute; for kosmetiske  \r\n\r\n produkter og &quot;non-food&quot; produkter (SCCNFP) (3), og er n&aelig;rmere  \r\n\r\n beskrevet i kapitel 2 i denne vejledning.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Endvidere skal den ansvarlige for markedsf&oslash;ringen  \r\n\r\n (producenten/import&oslash;ren) af det kosmetiske produkt i Danmark have  \r\n\r\n passende faglige kvalifikationer eller erfaringer i henhold til dansk  \r\n\r\n lovgivning og g&aelig;ldende praksis.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Hvis adressen p&aring; produktet er dansk, er det  \r\n\r\n Milj&oslash;styrelsen, der skal rette henvendelse til den  \r\n\r\n p&aring;g&aelig;ldende virksomhed, uanset om det er kontrolmyndighederne i  \r\n\r\n Danmark eller i et andet EU-land, der &oslash;nsker at se oplysningerne.  \r\n\r\n P&aring; en meget stor del af de kosmetiske produkter, der s&aelig;lges i  \r\n\r\n Danmark, st&aring;r der anf&oslash;rt en adresse p&aring; et firma i et andet  \r\n\r\n EU-land. Hvis Milj&oslash;styrelsen &oslash;nsker at unders&oslash;ge et  \r\n\r\n s&aring;dan produkt n&aelig;rmere, skal Milj&oslash;styrelsen rette  \r\n\r\n henvendelse til de ansvarlige myndigheder i det land, hvor adressen findes,  \r\n\r\n og anmode myndighederne her om at vurdere de relevante oplysninger.  \r\n\r\n Tilsvarende skal myndigheder i andre lande kontakte Milj&oslash;styrelsen,  \r\n\r\n hvis de &oslash;nsker en vurdering af oplysninger i et dossier, der befinder  \r\n\r\n sig i her i landet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Produktoplysningerne beh&oslash;ver kun at v&aelig;re  \r\n\r\n tilg&aelig;ngelige i &eacute;t EU-land. Hvor der angives flere firmaadresser  \r\n\r\n p&aring; etiketten, kan  det sted hvor dossieret opbevares eventuelt  \r\n\r\n v&aelig;re understreget. Fremstilles produktet i andre lande inden for EU,  \r\n\r\n kan fabrikanten v&aelig;lge en enkelt adresse, hvor oplysningerne holdes til  \r\n\r\n r&aring;dighed. Der vil endvidere v&aelig;re mulighed for, at  \r\n\r\n produktoplysningerne i praksis findes i hoveds&aelig;der, tekniske afdelinger  \r\n\r\n eller administrative afdelinger o.lign., ogs&aring; selv om disse er adskilt  \r\n\r\n fra det egentlige fabrikationssted. S&aring;fremt Milj&oslash;styrelsen  \r\n\r\n anmoder om, at oplysningerne stilles til r&aring;dighed, skal de  \r\n\r\n &oslash;nskede oplysninger kunne f&aring;s ved henvendelse til den i § 17  \r\n\r\n n&aelig;vnte adresse.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I tilf&aelig;lde af l&oslash;nproduktion vil  \r\n\r\n l&oslash;nproducentens navn og adresse (land) typisk ikke st&aring; p&aring;  \r\n\r\n emballagen. Det vil derimod navn og adresse (land) p&aring; det firma, der  \r\n\r\n har bestilt produktionen og som markedsf&oslash;rer produktet. Et dansk  \r\n\r\n firma, hvis adresse st&aring;r p&aring; det kosmetiske produkt, skal - uanset  \r\n\r\n om produktet markedsf&oslash;res i Danmark eller i andre EU-lande,  \r\n\r\n s&aring;ledes s&oslash;rge for at eventuelle udenlandske  \r\n\r\n l&oslash;nproducenter kan levere produktoplysninger efter retningslinjerne i  \r\n\r\n denne vejledning.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138666\">1.3 Udformning og  \r\n\r\n fremsendelse af oplysninger</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Produktoplysninger/dossier skal v&aelig;re  \r\n\r\n tilg&aelig;ngelige for Milj&oslash;styrelsen p&aring; dansk eller engelsk.  \r\n\r\n Det er derfor vigtigt at sikre, at eventuelle udenlandske  \r\n\r\n l&oslash;nproducenter eller underleverand&oslash;rer kan levere oplysninger  \r\n\r\n p&aring; disse sprog.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Som udgangspunkt vil Milj&oslash;styrelsen kr&aelig;ve, at  \r\n\r\n de &oslash;nskede oplysninger tilsendes Milj&oslash;styrelsen. Det b&oslash;r  \r\n\r\n dog understreges, at Milj&oslash;styrelsen, typisk ikke vil udbede sig et  \r\n\r\n helt dossier for et kosmetisk produkt, men at der snarere vil v&aelig;re tale  \r\n\r\n om specifikke sp&oslash;rgsm&aring;l til udvalgte dele af dossieret.  \r\n\r\n Oplysningerne kan enten leveres p&aring; papir eller p&aring; elektronisk  \r\n\r\n form og skal v&aelig;re tilg&aelig;ngelige for Milj&oslash;styrelsen inden  \r\n\r\n for 2 d&oslash;gn.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det vil s&aring;ledes v&aelig;re undtagelsen, at  \r\n\r\n Milj&oslash;styrelsen afl&aelig;gger bes&oslash;g p&aring; virksomheden for  \r\n\r\n under en gennemgang af dossieret at udv&aelig;lge de dele, som man  \r\n\r\n &oslash;nsker en kopi af.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Milj&oslash;styrelsen behandler oplysningerne  \r\n\r\n fortroligt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I bilag 1 til denne vejledning findes et forslag til  \r\n\r\n checkliste til fremskaffelse af oplysninger om kosmetik. Herudover er der i  \r\n\r\n bilag 2 en litteraturliste med forslag til opslagsv&aelig;rker, der er egnede  \r\n\r\n til indhentning af oplysninger til udarbejdelse af den generelle  \r\n\r\n toksikologiske profil for r&aring;varerne. Bilag 3 er en beskrivelse af den  \r\n\r\n faglige baggrund for unders&oslash;gelse af kosmetiske produkters  \r\n\r\n p&aring;st&aring;ede virkning.</P>  \r\n\r\n<B><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138667\">2 Krav til  \r\n\r\n produktoplysninger/dossier</A></P>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For alle kosmetiske produkter skal f&oslash;lgende  \r\n\r\n oplysninger v&aelig;re tilg&aelig;ngelige:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Produktets sammens&aelig;tning, Kap. 2.1</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Fysisk/kemiske og mikrobiologiske specifikationer, Kap. 2.2</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Fabrikationsmetoden, Kap. 2.3</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Sikkerhedsevaluering af det f&aelig;rdige produkt, Kap. 2.4</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Uddannelseskrav for den/de ansvarlige for sikkerhedsevalueringen, Kap.  \r\n\r\n 2.5</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  U&oslash;nskede virkninger for menneskers sundhed, Kap. 2.6</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Bevis for p&aring;st&aring;ede virkninger, Kap. 2.7</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I det f&oslash;lgende vil de enkelte oplysninger, der  \r\n\r\n kr&aelig;ves, blive gennemg&aring;et n&aelig;rmere.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138668\">2.1 Produktets  \r\n\r\n sammens&aelig;tning</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">If&oslash;lge bekendtg&oslash;relsen skal f&oslash;lgende  \r\n\r\n oplyses:</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">1)&#9;Midlets kvalitative og kvantitative formel; for  \r\n\r\n s&aring; vidt ang&aring;r parfumerede forbindelser og parfumer  \r\n\r\n begr&aelig;nses disse oplysninger til forbindelsens navn og kodenummer samt  \r\n\r\n leverand&oslash;rens identitet.</P> </DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Den fuldst&aelig;ndige sammens&aelig;tning af produkterne  \r\n\r\n skal oplyses, med angivelse af de enkelte r&aring;varers handelsnavn og  \r\n\r\n &oslash;vrige identitet (kvalitativ), og med m&aelig;ngdeangivelse for hver  \r\n\r\n enkelt r&aring;vare i v&aelig;gtprocent (kvantitativ).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">R&aring;varerne kan f.eks. v&aelig;re:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Bl&oslash;dg&oslash;rere, fugtighedsgivende stoffer,  \r\n\r\n stabilisatorer, fortykkelsesmidler, emulgatorer, farvestoffer,  \r\n\r\n konserveringsmidler, aromastoffer/parfumestoffer mv.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Hver enkelt stof i en r&aring;vare, herunder ogs&aring;  \r\n\r\n evt. konserveringsmidler i en r&aring;vare, skal entydigt identificeres,  \r\n\r\n f.eks. ud fra f&oslash;lgende oplysninger:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  INCI-navn.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  CAS-nr.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Kemisk navn, (f.eks. EINECS eller IUPAC navne).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Synonymer (f.eks. betegnelsen i CFTA, WHO eller den Europ&aelig;iske  \r\n\r\n Farmakop&eacute;).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  EINECS nr./ ELINCS nr.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Bruttoformel, hvis muligt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Struktur formel, hvis muligt, (eks. CH<SUB>3</SUB>-CO-CH<SUB>3</SUB>).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n  Fremstillingsmetode/oprindelse.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ved brug af materiale fra planter, plantedele eller dyr  \r\n\r\n (f.eks. presset saft, ekstrakt, stivelse eller gelatine) skal f&oslash;lgende  \r\n\r\n oplyses (se i &oslash;vrigt Kap. 2.2.2 side 10):</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">- Hvilken plante/dyr der er anvendt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">- Hvilken del af planten/dyret materialet stammer fra.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For planteekstrakter, der indg&aring;r i det f&aelig;rdige  \r\n\r\n produkt udelukkende som parfume (&aelig;teriske olier) og for andre parfumer  \r\n\r\n og parfumerede forbindelser, der ofte best&aring;r af mange forskellige  \r\n\r\n duftstoffer, kan oplysningerne om sammens&aelig;tningen begr&aelig;nses til  \r\n\r\n forbindelsens navn og kodenummer samt leverand&oslash;rens identitet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Tilsvarende g&aelig;lder for de syntetisk fremstillede  \r\n\r\n aroma- og parfumer&aring;varer. Aroma- og parfumer&aring;varer best&aring;r  \r\n\r\n ofte af mange forskellige duftstoffer, og blandinger p&aring; op til 10 - 300  \r\n\r\n forskellige stoffer er set. Det er &oslash;nskeligt, at de kemiske navne for  \r\n\r\n de sundhedsm&aelig;ssigt mest bet&aelig;nkelige duftstoffer samt for de  \r\n\r\n stoffer, der indg&aring;r som hovedkomponenter i aromaen/parfumen  \r\n\r\n oplyses.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138669\">2.2 Fysisk/kemiske  \r\n\r\n og mikrobiologiske specifikationer</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138670\">2.2.1 Generelt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">If&oslash;lge bekendtg&oslash;relsen skal f&oslash;lgende  \r\n\r\n oplyses:</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">2)&#9;R&aring;varernes og det f&aelig;rdige produkts  \r\n\r\n fysisk/kemiske og mikrobiologiske specifikationer samt kriterierne for renhed  \r\n\r\n og mikrobiologisk kontrol af de kosmetiske midler.</P></DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For yderligere identifikation af r&aring;varerne og det  \r\n\r\n f&aelig;rdige produkt skal disse karakteriseres ved deres analytiske  \r\n\r\n specifikationer. Relevante fysisk/ kemiske specifikationer skal angives for  \r\n\r\n hver ingrediens samt for det f&aelig;rdige produkt. Is&aelig;r de  \r\n\r\n fysisk/kemiske egenskaber, der har indflydelse p&aring; sikkerheden ved  \r\n\r\n anvendelsen som kosmetisk produkt skal oplyses. Disse specifikationer skal  \r\n\r\n bl.a. danne grundlag for den evaluering af sikkerheden med hensyn til  \r\n\r\n menneskers sundhed ved brug af det f&aelig;rdige produkt, som skal  \r\n\r\n udf&oslash;res under Kap.2.4.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Specifikationerne og andre relaterede kontrolkriterier for  \r\n\r\n b&aring;de r&aring;materialer og det f&aelig;rdige produkt, skal bestemmes i  \r\n\r\n forhold til typen og brugen af de enkelte r&aring;materialer og den type  \r\n\r\n produkt, de skal anvendes i.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Specifikationerne skal omfatte angivelse af de benyttede  \r\n\r\n analysemetoder med reference til analysecertifikater, samt oplysning om  \r\n\r\n acceptgr&aelig;nser for de beskrevne tests.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">S&aring;fremt varepr&oslash;ver findes, er  \r\n\r\n Milj&oslash;styrelsen berettiget til at f&aring; disse udleveret, hvis  \r\n\r\n Milj&oslash;styrelsen &oslash;nsker at foretage analyse af de enkelte  \r\n\r\n r&aring;varer.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138671\">2.2.2 Fysisk/kemiske  \r\n\r\n specifikationer for r&aring;varerne</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">En passende specifikation for r&aring;varen kan v&aelig;re  \r\n\r\n baseret p&aring; f&oslash;lgende:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Fysiske karakteristika: F.eks. tilstandsform (flydende, fast etc.),  \r\n\r\n massefylde, farve og lugt (skarp, s&oslash;d etc.) og evt. damptryk, smelte-  \r\n\r\n og kogepunkt, brydningsindeks, flammepunkt og viskositet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Kemiske karakteristika: F.eks. syre-base-egenskaber (pH), oxiderende  \r\n\r\n egenskaber og opl&oslash;selighed.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Stabilitet, f.eks. stabilitet ved lys-, fugt- og  \r\n\r\n temperaturp&aring;virkning.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Vandindhold, hvis stoffet er hygroskopisk eller nedbrydes ved fugt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;R&aring;varens identifikation, bestemt ved f.eks. IR, GC/MS, HPLC/MS,  \r\n\r\n HPLC/UV og AAS.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Endvidere angives r&aring;varens funktion i det  \r\n\r\n f&aelig;rdige produkt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Hvis r&aring;varen er beskrevet i en farmakop&eacute;, kan  \r\n\r\n man anvende monografien herfra. Milj&oslash;styrelsen anser den  \r\n\r\n europ&aelig;iske, den britiske, den franske, den japanske og den amerikanske  \r\n\r\n farmakop&eacute; for egnede i denne sammenh&aelig;ng.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ved r&aring;varer udvundet fra planter, eller  \r\n\r\n r&aring;varer som er dele af planter, kan f&oslash;lgende oplyses for  \r\n\r\n n&aelig;rmere identifikation:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;Botanisk navn og familie.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Hvilken del af planten, der anvendes.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">3.&#9;Hvor planten stammer fra geografisk.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">4.&#9;Hvorn&aring;r planten er h&oslash;stet og hvor langt  \r\n\r\n planten var n&aring;et i v&aelig;ksten.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">5.&#9;Behandling med pesticider under v&aelig;ksten.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">6.&#9;Fremstillingsprocessen, herunder evt. ekstraktion,  \r\n\r\n destillation eller oprensning.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">7.&#9;Kommerciel form, herunder om der er tale om et  \r\n\r\n  pulver eller en opl&oslash;sning, samt  evt. opl&oslash;sningsmiddel.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">8.&#9;Karakteristiske indholdsstoffer, herunder evt.  \r\n\r\n aktive indholdsstoffer (i %), mikrobiologisk kvalitet samt urenheder i  \r\n\r\n &oslash;vrigt.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Generelt b&oslash;r materiale fra planter og plantedele  \r\n\r\n v&aelig;re unders&oslash;gt for rester af pesticider mm., radioaktivitet,  \r\n\r\n toksiske metaller, sandsynlige forurenende stoffer og forfalskninger. Hvis  \r\n\r\n r&aring;varen  indeholder aktive stoffer, der er beskrevet i en  \r\n\r\n farmakop&eacute;, b&oslash;r man f&oslash;lge de analysemetoder, der er  \r\n\r\n angivet herfor i farmakop&eacute;en.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Tilsvarende krav til identifikation kan v&aelig;re  \r\n\r\n relevante for r&aring;varer udvundet af dyr. Som eksempel kan n&aelig;vnes  \r\n\r\n v&aelig;v fra kv&aelig;g, f&aring;r og geder, hvor visse former for v&aelig;v  \r\n\r\n ikke er tilladte i kosmetiske produkter p&aring; grund af kogalskab (TSE),  \r\n\r\n jf. bilag 2 til kosmetikbekendtg&oslash;relsen.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138672\">2.2.3 Kriterier for  \r\n\r\n fysisk/kemisk renhed af r&aring;varerne</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Enhver kendt urenhed, som kan have en toksikologisk  \r\n\r\n effekt, skal oplyses med navn og indholdsniveau. Det kan f. eks. v&aelig;re  \r\n\r\n indhold af opl&oslash;sningsmiddelrester, f.eks. benzen i vaseline,  \r\n\r\n restmonomerer i polymere forbindelser, eksempelvis acrylamid, nitrosaminer i  \r\n\r\n alkanolamider, tungmetaller, pesticidrester etc.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Alle de urenheder, der opst&aring;r under  \r\n\r\n fremstillingsprocessen af r&aring;varerne, eller de nedbrydningsprodukter,  \r\n\r\n som dannes under stabilitetstesten skal identificeres. Identifikationen kan  \r\n\r\n f.eks. foretages ved hj&aelig;lp af HPLC, GC, AAS og IR.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138673\">2.2.4 Fysisk/kemiske  \r\n\r\n specifikationer for det f&aelig;rdige produkt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Relevante specifikationer oplyses for det f&aelig;rdige  \r\n\r\n produkt, herunder fysiske og kemiske specifikationer som n&aelig;vnt under  \r\n\r\n r&aring;varer, s&aring;ledes at den s&aelig;dvanlige kvalitet af produktet  \r\n\r\n kan garanteres ved hj&aelig;lp af disse.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138674\">2.2.5 Fysisk/kemisk renhed af  \r\n\r\n det f&aelig;rdige produkt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det er producentens ansvar, at det f&aelig;rdige produkt  \r\n\r\n ikke indeholder andre urenheder eller en st&oslash;rre m&aelig;ngde af de  \r\n\r\n urenheder end de, der er n&aelig;vnt i produktets specifikationer, for  \r\n\r\n eksempel nitrosaminer, og at disse urenheder ikke influerer p&aring;  \r\n\r\n sikkerheden for kosmetikproduktet.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138675\">2.2.6 Mikrobiologisk kontrol af  \r\n\r\n r&aring;varerne og det f&aelig;rdige kosmetiske produkt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det er vigtigt at begr&aelig;nse mikroorganismer i  \r\n\r\n kosmetiske produkter, b&aring;de for ikke at skade brugeren, og for at  \r\n\r\n produktet kan holde l&aelig;ngere og ikke hurtigt nedbrydes og  \r\n\r\n &oslash;del&aelig;gges. For eksempel vil vandholdige produkter ofte have en  \r\n\r\n begr&aelig;nset holdbarhed, da de is&aelig;r er f&oslash;lsomme overfor  \r\n\r\n  mikrobiel v&aelig;kst.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">R&aring;varer kan bidrage betydeligt til mikrobiel  \r\n\r\n forurening af produktet, alt afh&aelig;ngigt af deres natur og oprindelse, og  \r\n\r\n kravene til mikrobiel renhed b&oslash;r v&aelig;re beskrevet i  \r\n\r\n r&aring;varespecifikationerne. Is&aelig;r skal vand konstant  \r\n\r\n unders&oslash;ges for v&aelig;kst. Det kan eventuelt vise sig at v&aelig;re  \r\n\r\n n&oslash;dvendigt at sterilisere vandet efter en eventuel demineralisering  \r\n\r\n for at opn&aring; en tilstr&aelig;kkelig ren kvalitet vand, da  \r\n\r\n ionbytterkolonner ofte kan v&aelig;re forurenede med mikroorganismer.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ved fasts&aelig;ttelse af kriterier for mikrobiel  \r\n\r\n forurening skelnes der mellem f&oslash;lgende produktkategorier:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;Produkter til b&oslash;rn under 3 &aring;r,  \r\n\r\n hudprodukter, beregnet til at forblive p&aring; huden (&quot;leave-on&quot;  \r\n\r\n produkter), og produkter beregnet til &oslash;jenomgivelser og  \r\n\r\n slimhinder.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Andre produkter, herunder produkter beregnet til at  \r\n\r\n skylles af (&quot;rinse off&quot; produkter).</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Milj&oslash;styrelsen anser f&oslash;lgende niveauer for  \r\n\r\n at v&aelig;re acceptable med hensyn til mikrobiel forurening:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ad 1.)</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Der skal v&aelig;re mindre end 10<SUP>2</SUP> aerobe  \r\n\r\n bakterier og svampe i alt pr. gram eller pr. milliliter af r&aring;varen  \r\n\r\n eller det f&aelig;rdige produkt</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ad 2.)</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Der skal v&aelig;re mindre end 10<SUP>3</SUP> aerobe  \r\n\r\n bakterier og 10<SUP>2</SUP> svampe pr. gram eller pr. milliliter af  \r\n\r\n r&aring;varen eller det f&aelig;rdige produkt.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Desuden m&aring; f&oslash;lgende specifikke  \r\n\r\n mikroorganismer ikke v&aelig;re til stede i kosmetiske produkter:</P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Staphylococcus aureus</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Pseudomonas aeruginosa</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Enterobacteriaceae</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Candida albicans</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Sandsynligheden for forekomst af de n&aelig;vnte  \r\n\r\n mikroorganismer er dog yderst begr&aelig;nset under de rene  \r\n\r\n fremstillingsforhold, der skal v&aelig;re til stede for at  \r\n\r\n kosmetikprodukterne kan overholde kravet om h&oslash;jst 10 <SUP>2</SUP>  \r\n\r\n bakterier og svampe. Test for disse kan derfor generelt udelades, n&aring;r  \r\n\r\n ovenfor n&aelig;vnte krav er opfyldt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Et passende antal pr&oslash;ver p&aring; mindst 1-10 g  \r\n\r\n eller 1-10 ml udtages til kontrol. Pr&oslash;vem&aelig;ngden og hyppigheden  \r\n\r\n af kontrollen afh&aelig;nger meget af, hvilken sammens&aelig;tning og type af  \r\n\r\n produkt, der er tale om. Kontrollen kan ogs&aring; v&aelig;re afh&aelig;ngig  \r\n\r\n af, hvor ofte produktet produceres. En rettesnor for fastl&aelig;ggelse af  \r\n\r\n pr&oslash;veudtagning kan v&aelig;re, at de f&oslash;rste 3 batch testes for  \r\n\r\n at f&aring; et indtryk af de normale produktionsforhold. P&aring; baggrund af  \r\n\r\n erfaringer fra disse test, sammenholdt med erfaringer fra  \r\n\r\n belastningsfors&oslash;g (se nedenfor) fastl&aelig;gges derefter, om det er  \r\n\r\n n&oslash;dvendigt at teste alle batch, eller om test af f.eks. hver 3., hver  \r\n\r\n 5. eller hver 10. etc. vil v&aelig;re en tilstr&aelig;kkelig kontrol.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">En egnet fremgangsm&aring;de til mikrobiologisk kontrol af  \r\n\r\n kosmetiske f&aelig;rdigvarer findes i den europ&aelig;iske farmakop&eacute;,  \r\n\r\n &quot;Total viable aerobic count&quot;, ( Ph.Eur. 2.6.12)  og &quot;Test for  \r\n\r\n specified micro-organisms&quot; (Ph.Eur. 2.6.13.), (4).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">De enkelte producenter kan selv foretage den  \r\n\r\n mikrobiologiske kontrol af kosmetikprodukterne. For at kontrollen  \r\n\r\n udf&oslash;res korrekt, vil det bl.a. kr&aelig;ve kontrollerede, rene  \r\n\r\n lokaler, mikrobiologisk viden og udstyr. Testen for de specielle bakterier og  \r\n\r\n svampe er mere kr&aelig;vende at udf&oslash;re. </P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Under udviklingen<B> </B>af et nyt kosmetikprodukt, eller  \r\n\r\n ved &aelig;ndring af de best&aring;ende produkter, er det vigtigt at sikre at  \r\n\r\n produktet har antimikrobielle egenskaber, s&aring;ledes at indholdet af  \r\n\r\n bakterier og svampe ikke volder skade p&aring; produkt eller bruger. Dette  \r\n\r\n kan ske enten via selve indholdsstoffernes antimikrobielle egenskaber eller  \r\n\r\n ved hj&aelig;lp af tils&aelig;tning af egnede konserveringsmidler.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Effektiviteten af kosmetikprodukternes antimikrobielle  \r\n\r\n egenskaber kan unders&oslash;ges ved hj&aelig;lp af belastningsfors&oslash;g,  \r\n\r\n (Challenge test). Ved denne test, uds&aelig;ttes produktet for en  \r\n\r\n n&aelig;rmere bestemt m&aelig;ngde mikroorganismer (10<SUP>5</SUP>-10<SUP>6  \r\n\r\n</SUP>kim/ml). N&aring;r der ved normal brug eller opbevaring er risiko for  \r\n\r\n infektion af brugeren eller for forringelse af produktet, skal denne test  \r\n\r\n v&aelig;re foretaget.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Belastningsfors&oslash;g er n&aelig;rmere beskrevet i  \r\n\r\n &quot;Efficacy of antimicrobial preservation&quot; (Ph.Eur. 5.1.3 ) (4). Her  \r\n\r\n fremg&aring;r det, hvordan hele proceduren er for tils&aelig;tning af  \r\n\r\n mikroorganismer, udtagning af pr&oslash;ver og t&aelig;lling af antallet af  \r\n\r\n mikroorganismer, der overlever indenfor de angivne tidsrum. Det tekniske  \r\n\r\n vejledningsdokument fra SCCNFP (3) angiver, at de mikroorganismer, der skal  \r\n\r\n anvendes i testen, skal v&aelig;re <I>Staphylococcus aureus, Pseudomonas  \r\n\r\n aeruginosa </I>og <I>Candida albicans,</I> men test med andre mikroorganismer  \r\n\r\n kan i s&aelig;rlige tilf&aelig;lde ogs&aring; v&aelig;re  \r\n\r\n n&oslash;dvendige.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For kosmetiske produkter anbefales det at f&oslash;lge  \r\n\r\n acceptkriterierne beskrevet i U.S.P. (Antimicrobial Preservation -  \r\n\r\n Effectiveness) (5). Dette medf&oslash;rer, at bakterierne skal v&aelig;re  \r\n\r\n reduceret til 0,1% af startkoncentrationen efter 14 dage, og at  \r\n\r\n koncentrationen af bakterier efter yderligere 14 dage ikke m&aring;  \r\n\r\n v&aelig;re for&oslash;get. For svampe m&aring; koncentrationen efter 14 dage  \r\n\r\n ikke v&aelig;re h&oslash;jere end startkoncentrationen, og den skal  \r\n\r\n v&aelig;re p&aring; samme niveau efter yderligere 14 dage.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">De antimikrobielle egenskaber for produktet er acceptable,  \r\n\r\n hvis der ses et signifikant fald eller ingen stigning i antallet af  \r\n\r\n mikroorganismer, n&aring;r produktet testes under hensyntagen til den  \r\n\r\n p&aring;t&aelig;nkte opbevaring og anvendelse. Det er vigtigt i denne  \r\n\r\n sammenh&aelig;ng ogs&aring; at unders&oslash;ge om produktets emballage  \r\n\r\n beskytter indholdet tilstr&aelig;kkeligt. Yderligere tils&aelig;tning af  \r\n\r\n konserveringsmidler er ikke hensigtsm&aelig;ssig, og tils&aelig;tning af en  \r\n\r\n h&oslash;jere dosis konserveringsmiddel m&aring; p&aring; ingen m&aring;de  \r\n\r\n erstatte kravene om god fabrikationspraksis.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Belastningsfors&oslash;get b&oslash;r gentages for  \r\n\r\n produktet, hvis der opst&aring;r tvivl om, hvorvidt produktet er konserveret  \r\n\r\n tilstr&aelig;kkeligt. Det skal understreges, at belastningsfors&oslash;g ikke  \r\n\r\n erstatter rutinem&aelig;ssig kontrol.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138676\">2.3  \r\n\r\n Fabrikationsmetoden</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138677\">2.3.1 Generelt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">If&oslash;lge kosmetikbekendtg&oslash;relsen er  \r\n\r\n f&oslash;lgende fastlagt for selve fremstillingen af kosmetikprodukterne og  \r\n\r\n skal oplyses:</P><DIR>  \r\n\r\n<B><P>3) Fabrikationsmetoden i overensstemmelse med god fabrikationspraksis,  \r\n\r\n s&aring;ledes at et kosmetisk produkt produceret under normale forhold ikke  \r\n\r\n udg&oslash;r fare for menneskets sundhed og sikkerhed.</P></DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det anbefales at f&oslash;lge retningslinierne for god  \r\n\r\n fabrikationspraksis for kosmetiske produkter: Guidelines for Good  \r\n\r\n Manufacturing Practice of Cosmetic Products (GMPC) fra EU (6). Det skal  \r\n\r\n understreges, at for at kunne leve op til de &oslash;vrige krav i dossieret,  \r\n\r\n er det vigtigt, at der er fuld sporbarhed i produktionen.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Fabrikationsmetoden skal v&aelig;re beskrevet med samtlige  \r\n\r\n relevante pro-cestrin. Et dokumentationssystem for alle trin i produktionen  \r\n\r\n skal opstilles med henvisninger til journalen for fabrikationsserien  \r\n\r\n (batchjournalen) for f&aelig;rdigvaren samt til batchjournaler for  \r\n\r\n r&aring;varerne. Beskrivelsen af fremstillingsmetoden skal bl.a.  \r\n\r\n omfatte:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;En veldefineret fremstillingsprocedure der  \r\n\r\n d&aelig;kker alle trin i produktionen, fastlagt ved en  \r\n\r\n sammens&aelig;tningsforskrift, en produktionsforskrift samt en  \r\n\r\n pakkeinstruktion, herunder valg af egnet emballage, s&aring; produktet  \r\n\r\n bevarer sin kvalitet. Alle afvigelser fra forskrifterne skal rapporteres.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Passende produktionsfaciliteter, herunder personale  \r\n\r\n og dets uddannelse, apparatur og produktionsudstyr og krav til  \r\n\r\n reng&oslash;ring af disse samt en god kvalitet af r&aring;varer.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">3.&#9;Kvalitetskontrol med passende, veldefinerede og  \r\n\r\n opdaterede testmetoder.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">4.&#9;En effektiv produktionsjournal, der for hvert  \r\n\r\n produkt skal indeholde mindst:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Handelsnavn, internt kodenummer etc.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Batchnummer og dato.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Reference til specifikationer og kontrolmetoder.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Resultatet af kontroltest af produktet samt initialer  \r\n\r\n for den person, der har udf&oslash;rt unders&oslash;gelserne.</P></DIR>  \r\n\r\n</DIR>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138678\">2.3.2  \r\n\r\n L&oslash;nproduktion</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I tilf&aelig;lde af l&oslash;nproduktion er det vigtigt,  \r\n\r\n at specifikationerne for produkterne er klare og utvetydige, samt at den  \r\n\r\n ansvarlige for markedsf&oslash;ringen sikrer, at producenten lever op til  \r\n\r\n ovenn&aelig;vnte krav (Kap. 2.3.1), og har de n&oslash;dvendige  \r\n\r\n produktionsfaciliteter, udstyr, personale etc. Endvidere skal forskrifter,  \r\n\r\n specifikationer etc. v&aelig;re tilg&aelig;ngelige p&aring; et sprog, der kan  \r\n\r\n forst&aring;s i det land, hvorfra markedsf&oslash;ringen sker.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Der b&oslash;r v&aelig;re en skriftlig aftale  \r\n\r\n d&aelig;kkende hele fremstillingsprocessen, og den ansvarlige for  \r\n\r\n markedsf&oslash;ringen b&oslash;r j&aelig;vnligt foretage kontrol af, om  \r\n\r\n l&oslash;nproducenten lever op til de definerede specifikationer.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138679\">2.4  \r\n\r\n Sikkerhedsevaluering af det f&aelig;rdige produkt</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138680\">2.4.1 Generelt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">If&oslash;lge bekendtg&oslash;relsen g&aelig;lder  \r\n\r\n f&oslash;lgende vedr&oslash;rende vurdering af kosmetikprodukternes  \r\n\r\n eventuelle sundhedsfarlige egenskaber:</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">4)&#9;En evaluering af sikkerheden med hensyn til  \r\n\r\n menneskets sundhed ved brug af det f&aelig;rdige produkt. Med henblik  \r\n\r\n herp&aring; tager fabrikanten f&oslash;lgende i betragtning: ingrediensernes  \r\n\r\n generelle toksikologiske profil, deres kemiske struktur og de vilk&aring;r,  \r\n\r\n hvorunder de anvendes.</P></DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Der skal fremskaffes tilstr&aelig;kkelig information til  \r\n\r\n at kunne vurdere sikkerheden ved det f&aelig;rdige kosmetiske produkt. De  \r\n\r\n enkelte stoffers farlighed skal vurderes med baggrund i kriterierne for  \r\n\r\n stoffers farlighed, som er n&aelig;rmere beskrevet i  \r\n\r\n Klassificeringsbekendtg&oslash;relsen (7). Det er hensigten at indhentning af  \r\n\r\n toksikologiske oplysninger om indholdsstofferne i den g&aelig;ngse  \r\n\r\n toksikologiske litteratur (se bilag 2) generelt skal give en  \r\n\r\n tilstr&aelig;kkelig baggrund for vurderingen af det f&aelig;rdige produkt,  \r\n\r\n uden behov for at skulle teste det f&aelig;rdige produkt p&aring; dyr eller  \r\n\r\n mennesker. Dog kan yderligere tests i s&aelig;rlige tilf&aelig;lde, som  \r\n\r\n beskrevet i det f&oslash;lgende, blive n&oslash;dvendige.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For flere indholdsstoffer i kosmetiske produkter er der  \r\n\r\n allerede fastlagt detaljerede retningslinjer for anvendelse i  \r\n\r\n kosmetikbekendtg&oslash;relsens bilag 3 til 6. Tilsvarende bilag findes i  \r\n\r\n kosmetikdirektivet. Fastl&aelig;ggelsen af anvendelsesbegr&aelig;nsningerne i  \r\n\r\n de omtalte bilag er foretaget af EU p&aring; baggrund af vurderinger af,  \r\n\r\n hvorvidt stofferne kan anvendes sikkert i kosmetiske produkter p&aring; en af  \r\n\r\n de n&aelig;rmere angivne m&aring;der. S&aring;fremt indholdsstofferne  \r\n\r\n anvendes p&aring; den angivne m&aring;de, vil sikkerhedsevalueringen af det  \r\n\r\n p&aring;g&aelig;ldende stof som hovedregel kunne ske med en henvisning til,  \r\n\r\n at stoffet er godkendt til den aktuelle anvendelse. Indhentningen af  \r\n\r\n toksikologiske oplysninger om disse indholdsstoffer vil dermed v&aelig;re  \r\n\r\n un&oslash;dvendig i disse tilf&aelig;lde. Anvendes indholdsstoffet derimod  \r\n\r\n til andre form&aring;l end de, der er fastlagt i  \r\n\r\n kosmetikbekendtg&oslash;relsen, eller i andre koncentrationer (hvilket f.eks.  \r\n\r\n er tilladt for visse konserveringsmidler), er en selvst&aelig;ndig vurdering  \r\n\r\n fortsat n&oslash;dvendig.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det skal dog understeges, at det altid er den virksomhed,  \r\n\r\n der markedsf&oslash;rer et kosmetisk produkt, der er ansvarlig for  \r\n\r\n sikkerheden af produktet, jf. kosmetikbekendtg&oslash;relsens § 9. Ved  \r\n\r\n sikkerhedsevalueringen tages der derfor ogs&aring; h&oslash;jde for evt. nye  \r\n\r\n almindeligt kendte oplysninger om et stofs egenskaber, hvis s&aring;danne  \r\n\r\n oplysninger vurderes at have betydning for produktets sikkerhed.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">En litteraturliste med forslag til opslagsv&aelig;rker,  \r\n\r\n der er egnede til indhentning af oplysninger til udarbejdelse af den  \r\n\r\n generelle toksikologiske profil for r&aring;varerne er vedlagt i bilag 2.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det er vigtigt, at de toksikologiske profiler for  \r\n\r\n stofferne holdes ajour i forhold til ny viden p&aring; omr&aring;det.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138681\">2.4.2 Den generelle  \r\n\r\n toksikologiske profil</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Vurderingen af stoffernes toksiske effekter er det  \r\n\r\n f&oslash;rste trin i sikker-hedsevalueringen. Sikkerhedsevalueringen skal  \r\n\r\n bygge p&aring; oplysninger om stofferne og resultater af test for  \r\n\r\n egenskaberne, n&aelig;vnt nedenfor. Der vil dog v&aelig;re tilf&aelig;lde,  \r\n\r\n hvor det ikke synes at v&aelig;re n&oslash;dvendigt, eller hvor det ikke er  \r\n\r\n muligt at fremskaffe den n&aelig;vnte dokumentation. I disse tilf&aelig;lde  \r\n\r\n gives en faglig begrundelse herfor.</P><DIR>  \r\n\r\n<DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;Akut toksicitet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Hudabsorption.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">3.&#9;Hudirritation.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">4.&#9;Slimhindeirritation.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">5.&#9;Hudsensibilisering.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">6.&#9;Subkronisk toksicitet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">7.&#9;Mutagenicitet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">8.&#9;Fototoksicitet og fotomutagenicitet (kun aktuelt ved  \r\n\r\n UV-lys absorberende stoffer).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">9.&#9;Humane data (kun s&aring;fremt der allerede er  \r\n\r\n tilg&aelig;ngelige data).</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">10.&#9;Toksikokinetik.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">11.&#9;Teratogenicitet, reproduktionstoksicitet,  \r\n\r\n carcinogenicitet, og yderligere genotoksicitet.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Tests b&oslash;r v&aelig;re udf&oslash;rt ved at bruge et  \r\n\r\n stof med de samme kemiske og fysiske karakteristika, som i det f&aelig;rdige  \r\n\r\n produkt. Ved anvendelse af en kendt r&aring;vare i en ny sammenh&aelig;ng,  \r\n\r\n skal man v&aelig;re omhyggelig med vurdering af publicerede data for  \r\n\r\n r&aring;varen, da den kan v&aelig;re testet som ingrediens i den type  \r\n\r\n produkt, som den almindeligvis anvendes i.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Vurderingen af de f&aelig;rdige kosmetikprodukters  \r\n\r\n sikkerhed kan generelt foretages p&aring; baggrund af viden om de enkelte  \r\n\r\n indholdsstoffers toksicitet. Dog kan det i s&aelig;rlige tilf&aelig;lde  \r\n\r\n v&aelig;re n&oslash;dvendigt med supplerende oplysninger:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hvis indholdsstoffets hudgennemtr&aelig;ngelighed eller irriterende  \r\n\r\n effekter &oslash;ges p&aring; grund af, at de &oslash;vrige stoffer i det  \r\n\r\n aktuelle kosmetiske produkt har en anden indflydelse p&aring; indholdsstoffet  \r\n\r\n end den, som er set i tidligere udf&oslash;rte unders&oslash;gelser af  \r\n\r\n stoffet, hvor stoffet blot er blandet med opl&oslash;sningsmiddel.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hvis et nyt farligt stof kan dannes ved sammenblanding af de enkelte  \r\n\r\n indholdsstoffer og p&aring;vises i det f&aelig;rdige  \r\n\r\n kosmetikprodukt.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Oplysningerne skal fremskaffes via data fremkommet ved  \r\n\r\n anvendelse af internationalt anerkendte testmetoder. Data kan opn&aring;s fra  \r\n\r\n anerkendte validerede alternative testmetoder <I>in vitro </I>(f.eks.  \r\n\r\n p&aring; v&aelig;v eller celler udtaget fra levende organismer), eller,  \r\n\r\n n&aring;r alternative metoder ikke anerkendes eller eksisterer, fra  \r\n\r\n fors&oslash;g <I>in vivo </I>( p&aring; levende dyr).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det anbefales at anvende de testmetoder som EU-  \r\n\r\n Kommissionen har angivet i R&aring;dets 67-direktiv (67/548/E&Oslash;F), med  \r\n\r\n senere &aelig;ndringer (8), (9), eller som beskrevet i  OECD guidelines  \r\n\r\n (10).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Hvis der findes humane kliniske observationer skal de  \r\n\r\n ogs&aring; vurderes. Humane data kan f.eks. fremskaffes fra:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Specifikke toksikologiske studier eller fra studier  \r\n\r\n udf&oslash;rt til andre regulatoriske form&aring;l, f.eks.  \r\n\r\n arbejdsmilj&oslash;sammenh&aelig;nge.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">-&#9;Leverand&oslash;ren af r&aring;varerne suppleret med  \r\n\r\n de data, der kan skaffes igennem databaser eller publiceret  \r\n\r\n litteratur.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ogs&aring; data fra tidlige forbrugerunders&oslash;gelser  \r\n\r\n kan muligvis have v&aelig;rdi i denne sammenh&aelig;ng, ligesom alle  \r\n\r\n erfaringer og indberetninger af u&oslash;nskede virkninger for produktet (se  \r\n\r\n Kap. 2.7) skal overvejes n&oslash;je.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138682\">2.4.3 Stoffets kemiske  \r\n\r\n struktur</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Stoffets kemiske struktur, egenskaber og strukturformel er  \r\n\r\n blevet beskrevet tidligere under Kap. 2.1 og 2.2. Endvidere er graden af  \r\n\r\n renhed bestemt. For alle relevante urenheder b&oslash;r den maximalt tilladte  \r\n\r\n koncentration af urenhederne defineres baseret p&aring; toksikologiske  \r\n\r\n oplysninger.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det er producentens ansvar, at der ikke er andre urenheder  \r\n\r\n eller st&oslash;rre m&aelig;ngder af urenheder, end de, der er kemisk  \r\n\r\n definerede eller teknologisk uundg&aring;elige, som kan have indflydelse  \r\n\r\n p&aring; sikkerheden af det f&aelig;rdige produkt.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138683\">2.4.4 Evaluering af  \r\n\r\n sikkerheden</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Evalueringen af sikkerheden ved et kosmetisk produkt  \r\n\r\n afh&aelig;nger i h&oslash;j grad af, hvordan produktet anvendes. Produktets  \r\n\r\n anvendelse har s&aring;ledes indflydelse p&aring;, hvor meget af produktet og  \r\n\r\n dermed af de enkelte indholdsstoffer, der vil kunne indtages, ind&aring;ndes  \r\n\r\n eller optages gennem hud eller slimhinder. Desuden har m&aelig;ngden af de  \r\n\r\n enkelte indholdsstoffer i de enkelte produkter ogs&aring; indflydelse  \r\n\r\n p&aring; sikkerhedsevalueringen.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">F&oslash;r en sikkerhedsevaluering og risikovurdering for  \r\n\r\n et kosmetikprodukt s&aelig;ttes i gang, skal selve anvendelsen v&aelig;re  \r\n\r\n n&oslash;je beskrevet. Dette kan ikke g&oslash;res generelt, men m&aring;  \r\n\r\n g&oslash;res &quot;case-by-case&quot;, alt afh&aelig;ngig af de enkelte  \r\n\r\n produkters unikke sammens&aelig;tning og anvendelse. En vurdering af, om  \r\n\r\n anvendelse af det kosmetiske produkt anses for sikkert for s&aelig;rligt  \r\n\r\n s&aring;rbare grupper, som f.eks. b&oslash;rn, skal som hovedregel  \r\n\r\n indg&aring; i risikovurderingen. I det mindste skal f&oslash;lgende faktorer  \r\n\r\n i risikovurderingen overvejes f&oslash;r v&aelig;gtning af de enkelte  \r\n\r\n indholdsstoffer:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Type af kosmetikprodukt, f.eks. shampoo, solcreme, tandpasta.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;P&aring;f&oslash;ringsmetoden, f.eks. masseret p&aring; huden med eller  \r\n\r\n uden efterf&oslash;lgende afvaskning, sprayet p&aring;, b&oslash;rstet  \r\n\r\n p&aring;.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Koncentrationen af de enkelte ingredienser i produktet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;M&aelig;ngden af produktet der p&aring;f&oslash;res ved normal brug.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hyppigheden af p&aring;f&oslash;ringerne, korttids-/ langtidsbrug.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Det totale hudomr&aring;de p&aring; kroppen, hvorp&aring; produktet  \r\n\r\n p&aring;f&oslash;res.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Typen af p&aring;f&oslash;ringsomr&aring;det, f.eks. slimhinder,  \r\n\r\n &oslash;jenvipper, solbr&aelig;ndt hud, l&aelig;ber.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Varigheden af kontakt, f.eks. afvaskelige produkter.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Forudseeligt misbrug, der kan for&oslash;ge p&aring;virkningen.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Type af forbruger, f.eks. b&oslash;rn, &aelig;ldre, folk med sart  \r\n\r\n hud.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;M&aelig;ngde, der kan tr&aelig;nge ind i og optages i kroppen.</P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Hvilken p&aring;virkning, der anses for at v&aelig;re  \r\n\r\n relevant ved sikkerhedsvurderingen af det enkelte produkt/stof,  \r\n\r\n afh&aelig;nger af den toksiske effekt der unders&oslash;ges. For toksiske  \r\n\r\n effekter som hudirritation eller fototoksicitet vil det f.eks. v&aelig;re  \r\n\r\n vigtigt at kende til p&aring;virkningen af stofferne pr. enhed hudareal, mens  \r\n\r\n det for en generel (systemisk) giftvirkning vil v&aelig;re p&aring;virkning  \r\n\r\n pr. enhed kropsv&aelig;gt, der er relevant.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">P&aring;virkningsvejen eller -vejene (f.eks. hud, hud  \r\n\r\n udsat for sollys, slimhinder, &oslash;jenvipper, indtagelse eller  \r\n\r\n ind&aring;nding) skal tages i betragtning ved hver risikovurdering af  \r\n\r\n produkterne, eller s&aring;fremt et testprogram skal s&aelig;ttes op. Andre  \r\n\r\n mulige p&aring;virkningsveje end de, produktet er beregnet til, skal  \r\n\r\n ogs&aring; tages i betragtning ved vurdering af sikkerheden, f.eks.  \r\n\r\n ind&aring;nding af h&aring;rspray, indtagelse af l&aelig;bestifter etc.  \r\n\r\n Eventuel yderligere eksponering for de problematiske stoffer fra andre kilder  \r\n\r\n end fra det kosmetiske produkt, b&oslash;r ogs&aring; indg&aring; i  \r\n\r\n risikovurderingen.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Desuden er anvendelse af kosmetikprodukter afh&aelig;ngig  \r\n\r\n af mange faktorer, som f.eks. &aring;rstider, mode, aldersgruppe, vaner,  \r\n\r\n nyhedsv&aelig;rdi. Da mange af disse faktorer &aelig;ndrer sig med tiden, vil  \r\n\r\n det ofte ikke v&aelig;re muligt at l&aelig;gge sig fast p&aring; et specifikt  \r\n\r\n p&aring;virkningsniveau for de enkelte typer af kosmetikprodukter.  \r\n\r\n Sikkerhedsevalueringen b&oslash;r derfor foretages enkeltvis for de  \r\n\r\n p&aring;g&aelig;ldende produkter.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Et teknisk vejledningsdokument fra EU oplyser eksempler  \r\n\r\n p&aring; typiske m&aelig;ngder af almindelige kosmetikprodukter, anvendt ved  \r\n\r\n almindelig brug af produkterne. Data er fra 1981 og 1993 (11).</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138684\">2.5  \r\n\r\n Uddannelseskrav for den/de ansvarlige for sikkerhedsevalueringen</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">If&oslash;lge bekendtg&oslash;relsen g&aelig;lder  \r\n\r\n f&oslash;lgende vedr&oslash;rende krav til uddannelse for den eller de, der  \r\n\r\n udf&oslash;rer sikkerhedsevalueringen for kosmetikprodukterne, som beskrevet  \r\n\r\n ovenfor i Kap. 2.4:</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">5)&#9;Navn og adresse p&aring; den eller de hertil  \r\n\r\n kvalificerede personer, som er ansvarlige for den i nr. 4 n&aelig;vnte  \r\n\r\n evaluering. Denne person skal have et eksamensbevis som defineret i artikel 1  \r\n\r\n i direktiv 89/48/E&Oslash;F inden for farmaci, toksikologi, dermatologi,  \r\n\r\n medicin eller en lignende disciplin.</P></DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det n&aelig;vnte direktiv handler om indf&oslash;relse af  \r\n\r\n en generel ordning for gensidig anerkendelse i EU af eksamensbeviser for  \r\n\r\n erhvervskompetencegivende videreg&aring;ende uddannelser.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det anbefales at vedl&aelig;gge et fuldt curriculum vitae  \r\n\r\n for personen med uddannelse, erhvervserfaring osv.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138685\">2.6  \r\n\r\n U&oslash;nskede virkninger for menneskers sundhed</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138686\">2.6.1 Generelt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">I f&oslash;lge bekendtg&oslash;relsen stilles der krav til  \r\n\r\n at data vedr&oslash;rende u&oslash;nskede virkninger skal oplyses:</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">6)&#9;De eksisterende data vedr&oslash;rende  \r\n\r\n u&oslash;nskede virkninger for menneskers sundhed fremkaldt af det kosmetiske  \r\n\r\n middel ved anvendelsen heraf.</P></DIR>  \r\n\r\n</B>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138687\">2.6.2 Registrering</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">De enkelte produkter beskrives med handelsnavn og aktuel  \r\n\r\n sammens&aelig;tning, samt hvilke reklamationer af u&oslash;nskede virkninger,  \r\n\r\n der har v&aelig;ret. Oplysningerne om de u&oslash;nskede virkninger skal  \r\n\r\n desuden omfatte indberetterens navn, adresse og datoen for indberetningen;  \r\n\r\n navn og adresse p&aring; indberetteren skal dog ikke indsendes til  \r\n\r\n myndighederne, men anvendes ved opf&oslash;lgning p&aring; sagen. Beskrivelse  \r\n\r\n af den u&oslash;nskede virkning skal ske med angivelse af, hvor p&aring;  \r\n\r\n kroppen virkningen blev konstateret, hvorn&aring;r virkningen opstod efter  \r\n\r\n p&aring;f&oslash;ring af kosmetikproduktet, og om produktet er anvendt  \r\n\r\n tidligere med eller uden en lignende reaktion.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For at f&aring; en st&oslash;rre v&aelig;rdi af  \r\n\r\n oplysningerne, m&aring; de ogs&aring; gerne indbefatte forbrugerens alder,  \r\n\r\n k&oslash;n og hvis muligt helbredsm&aelig;ssige status. Oplysninger om  \r\n\r\n u&oslash;nskede virkninger b&oslash;r ikke begr&aelig;nses til kun at  \r\n\r\n v&aelig;re de, der kommer fra en l&aelig;ge. Omhyggelige indberetningsdata  \r\n\r\n kan have v&aelig;rdi for b&aring;de evaluering af produktets sikkerhed og for  \r\n\r\n nyudvikling eller omformulering af produktet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Endvidere b&oslash;r producentens reaktion og  \r\n\r\n h&aring;ndtering af reklamationen oplyses. B&aring;de de korrigerende og de  \r\n\r\n forebyggende handlinger skal beskrives.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Data b&oslash;r mindst opbevares s&aring; l&aelig;nge  \r\n\r\n produktet findes p&aring; markedet.</P>  \r\n\r\n<B><I><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138688\">2.7 Bevis for  \r\n\r\n p&aring;st&aring;ede virkninger</A></P>  \r\n\r\n</B>  \r\n\r\n</I>  \r\n\r\n</FONT>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138689\">2.7.1 Generelt</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">If&oslash;lge bekendtg&oslash;relsen skal f&oslash;lgende  \r\n\r\n oplysninger v&aelig;re tilg&aelig;ngelige:</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">7)&#9;Beviserne for den p&aring;st&aring;ede virkning  \r\n\r\n af det kosmetiske middel, n&aring;r arten af virkningen eller midlet  \r\n\r\n begrunder det.</P></DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Det er s&aelig;rligt vigtigt at kunne dokumentere  \r\n\r\n virkninger, der har sundhedsm&aelig;ssig betydning for brugerne af produktet.  \r\n\r\n Som eksempel herp&aring; kan n&aelig;vnes beskyttelsesfaktoren i solcreme,  \r\n\r\n hvor der skal v&aelig;re dokumentation for, at den angivne beskyttelsesfaktor  \r\n\r\n yder den sikkerhed, som p&aring;st&aring;s. Ogs&aring; en r&aelig;kke andre  \r\n\r\n virkninger kan have sundhedsm&aelig;ssig betydning.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">S&aring;fremt et kosmetisk produkt p&aring;st&aring;s at  \r\n\r\n have en s&aelig;rlig virkning, der giver brugeren forventning om helt  \r\n\r\n specielle effekter ved produktet, skal denne virkning ligeledes kunne  \r\n\r\n dokumenteres, ogs&aring; selvom virkningen ikke har sundhedsm&aelig;ssig  \r\n\r\n betydning.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Den p&aring;st&aring;ede virkning af et kosmetisk produkt  \r\n\r\n skal bevises ud fra videnskabeligt korrekt udf&oslash;rte fors&oslash;g. I  \r\n\r\n det f&oslash;lgende beskrives kort en r&aelig;kke principper, der i den  \r\n\r\n forbindelse skal v&aelig;re overholdt. Bilag 3 i denne vejledning er vedlagt  \r\n\r\n som faglig baggrund og vil desuden n&aelig;rmere uddybe metoder og principper  \r\n\r\n til m&aring;linger af effekt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">De principper, som anvendes til vurdering og dokumentation  \r\n\r\n af virkninger og bivirkninger af medicinsk og ikke-medicinsk behandling, kan  \r\n\r\n direkte anvendes p&aring; brug af kosmetik.</P>  \r\n\r\n<FONT FACE=\"Arial\"><P><A NAME=\"_Toc500138690\">2.7.2 Principper for  \r\n\r\n fremskaffelse af data</A></P>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Milj&oslash;styrelsen forventer, at dokumentation for den  \r\n\r\n p&aring;st&aring;ede virkning af det kosmetiske produkt er baseret p&aring;  \r\n\r\n videnskabeligt korrekt udf&oslash;rte fors&oslash;g, og at m&aring;lingerne i  \r\n\r\n disse fors&oslash;g er relevante for den effekt, der p&aring;st&aring;s.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Unders&oslash;gelserne af den p&aring;st&aring;ede  \r\n\r\n virkning skal desuden v&aelig;re udf&oslash;rt p&aring; f&aelig;rdige  \r\n\r\n produkter, identiske med de, der markedsf&oslash;res.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Data indhentet fra laboratorieunders&oslash;gelser eller  \r\n\r\n fra litteraturen, bl.a. artikler fra videnskabelige tidsskrifter, for de  \r\n\r\n indholdsstoffer, fra hvilke virkningen forventes, kan ikke erstatte  \r\n\r\n dokumentation i form af en korrekt udf&oslash;rt unders&oslash;gelse af  \r\n\r\n virkningen af det f&aelig;rdige produkt. Disse data er i stedet  \r\n\r\n v&aelig;rdifulde som baggrundsdokumentation ved fastl&aelig;ggelse af en  \r\n\r\n relevant test og ved vurdering af opn&aring;ede data derfra.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Dokumentationen for en virkning af et stof m&aring; ikke  \r\n\r\n tages til indt&aelig;gt for en p&aring;st&aring;et virkning af det kosmetiske  \r\n\r\n produkt. Ligeledes m&aring; s&aring;danne resultater ikke modificeres i form  \r\n\r\n af fx anprisninger, s&aring;ledes at der fremkommer et andet indtryk af  \r\n\r\n produktet end det, der blev dokumenteret/fundet ved unders&oslash;gelsen af  \r\n\r\n det kosmetiske produkt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Dokumentationen for den p&aring;st&aring;ede virkning skal  \r\n\r\n v&aelig;re fremskaffet fra unders&oslash;gelser af produktets virkning  \r\n\r\n p&aring; mennesker. Det er vigtigt, at det kosmetiske produkts  \r\n\r\n p&aring;st&aring;ede virkning f&oslash;rst unders&oslash;ges, n&aring;r det  \r\n\r\n er sikret, at produktet ikke kan v&aelig;re til skade for menneskets  \r\n\r\n sundhed.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ved unders&oslash;gelser p&aring; mennesker er der  \r\n\r\n b&aring;de etiske og praktiske principper der skal overvejes, bl.a. Helsinki  \r\n\r\n Deklarationen vedr&oslash;rende beskyttelse af personer, der deltager i  \r\n\r\n fors&oslash;g, bestemmelser fra Registertilsynet og retningslinjer om god  \r\n\r\n fors&oslash;gspraksis, (Good Clinical Practice, GCP). Overholdelse af fuld  \r\n\r\n GCP forventes ikke at kunne opn&aring;s ved test af kosmetiske produkter, men  \r\n\r\n principper derfra forventes anvendt. EU s videnskabelige komit&eacute;  \r\n\r\n (SCCNFP) har desuden beskrevet flere grundl&aelig;ggende principper og  \r\n\r\n anbefalinger vedr&oslash;rende anvendelse af fors&oslash;gspersoner til  \r\n\r\n unders&oslash;gelse af kosmetiske produkter i bilag 12 til et teknisk  \r\n\r\n vejledningsdokument for kosmetiske produkter (3).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Der findes i dag flere non-invasive instrumentelle  \r\n\r\n metoder, hvor produkters p&aring;virkning af huden kan unders&oslash;ges  \r\n\r\n objektivt og uden indgreb i kroppen. Det er vigtigt, at m&aring;lingerne er  \r\n\r\n relevante for produktets p&aring;st&aring;ede virkning.  \r\n\r\n Brugerunders&oslash;gelser og unders&oslash;gelser af relevante effekter,  \r\n\r\n udf&oslash;rt af tr&aelig;net personale er ogs&aring; anvendelige metoder til  \r\n\r\n unders&oslash;gelse af produktets virkning p&aring; mennesker.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Der findes i dag ogs&aring; en r&aelig;kke <I>in vitro  \r\n\r\n</I>testmetoder, men disse giver generelt blot et groft indtryk af produktets  \r\n\r\n virkning p&aring; mennesker.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ved fremsendelse af data, skal testrapporten mindst  \r\n\r\n indeholde en beskrivelse af:</P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hvilke r&aring;varer og/eller produkter der er unders&oslash;gt.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Navn, titel, kvalifikationer og<B> </B>evt. curriculum vitae for den, der  \r\n\r\n har st&aring;et for unders&oslash;gelserne.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hvilken metode man har benyttet til indhentning af oplysningerne.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hvilke kriterier der er fastlagt for vurderingen.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Hvilke forhold i &oslash;vrigt der har v&aelig;ret for  \r\n\r\n gennemf&oslash;relsen af testen, f.eks. p&aring;f&oslash;ringstid/-frekvens,  \r\n\r\n -omr&aring;de, -m&aelig;ngde etc.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P></DIR>  \r\n\r\n<B><FONT FACE=\"Arial\" SIZE=4><P><A NAME=\"_Toc500138691\">Referenceliste</A></P><DIR>  \r\n\r\n<DIR>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;Bekendtg&oslash;relse om kosmetiske produkter.  \r\n\r\n Milj&oslash;- og Energiministeriets bekendtg&oslash;relse nr. 594 af 6. juni  \r\n\r\n 2000 eller efterf&oslash;lgende udgaver.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Kosmetikdirektivet 76/768/E&Oslash;F med senere  \r\n\r\n &aelig;ndringer.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">3.&#9;Notes for Guidance for Testing of Cosmetic  \r\n\r\n Ingredients for their Safety Evaluation, 3.rev. The Scientific Committee on  \r\n\r\n Cosmetic Products and Non-Food Products Intended for Consumers.  \r\n\r\n SCCNFP/0119/99 Final 23 June 1999.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">4.&#9;European Pharmacopoeia Supplement 2000, 3.ed.  \r\n\r\n Counsil of Europe, Strassbourg.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">5.&#9;The United States Pharmacopeia.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">6.&#9;Guidelines for Good Manufacturing Practice of  \r\n\r\n Cosmetic Products (GMPC), Council of Europe Publishing, 1995.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">7.&#9;Bekendtg&oslash;relse om klassificering,  \r\n\r\n emballering, m&aelig;rkning, salg og opbevaring af kemiske stoffer og  \r\n\r\n produkter. Milj&oslash;- og Energiministeriets bekendtg&oslash;relse nr. 734  \r\n\r\n af 31. juli 2000 eller efterf&oslash;lgende udgaver.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">8.&#9;Kommissionens direktiv 84/449/E&Oslash;F af 25.  \r\n\r\n april 1984, om sjette tilpasning til den tekniske udvikling af R&aring;dets  \r\n\r\n direktiv 67/548/E&Oslash;F om tiln&aelig;rmelse af lovgivning om  \r\n\r\n klassificering, emballering og m&aelig;rkning af farlige stoffer. Bilag B:  \r\n\r\n Metoder til bestemmelse af toksicitet.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">9.&#9;Kommissionens direktiv 92/69/E&Oslash;F af 31. juli  \r\n\r\n 1992 om syttende tilpasning til den tekniske udvikling af R&aring;dets  \r\n\r\n direktiv 67/548/E&Oslash;F om tiln&aelig;rmelse af lovgivning om  \r\n\r\n klassificering, emballering og m&aelig;rkning af farlige stoffer.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">10.&#9;OECD s Guidelines for the Testing of Chemicals.  \r\n\r\n Organisation for the Economic Cooperation and Development.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">11.&#9;Technical Guidance Document in Support of  \r\n\r\n Commission Directive 93/67/EEC on Risk Assessment for New Notified Substances  \r\n\r\n and Commission Regulation (EC) No 1488/94 on Risk Assessment for Existing  \r\n\r\n Substances, Part I.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n</DIR>  \r\n\r\n<A NAME=\"\"B1\"\"></A>\r\n\r\n<DIV CLASS=BILAG ID=\"B1\">  \r\n\r\n<HR width=70% align=center>  \r\n\r\n<B><FONT SIZE=4><P ALIGN=\"RIGHT\">Bilag 1</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Checkliste til fremskaffelse af oplysninger om  \r\n\r\n kosmetik</P>  \r\n\r\n</FONT>  \r\n\r\n<FONT SIZE=1><P ALIGN=\"JUSTIFY\">if&oslash;lge Milj&oslash;- og  \r\n\r\n Energiministeriets bekendtg&oslash;relse om kosmetiske produkter, § 32</P>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Handelsnavn _____________________________</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P><DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">1.&#9;Sammens&aelig;tning op til 100%</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Stofnavn/kemisknavn, CAS-nr., INCI-navn, EINECS/ELINCS,  \r\n\r\n %-indhold og funktion/beskrivelse af hvert indholdsstof i det kosmetiske  \r\n\r\n produkt </P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 1&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 2&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 3&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 4&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 5&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;osv.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">2. Fysisk/kemiske specifikationer for r&aring;varerne,  \r\n\r\n indhold af evt. urenheder</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 1&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 2&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 3&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 4&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 5&#9;se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;osv.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<B>Fysisk/kemiske specifikationer for  \r\n\r\n f&aelig;rdigvaren, indhold af evt. urenheder</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;</B>se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<B>Mikrobiologisk kontrol af r&aring;varerne</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;</B>se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<B>Mikrobiologisk kontrol af f&aelig;rdigvaren</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;</B>se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">3. Fabrikationsmetoden</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Produktionsforskrift, se bilag ____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Batchjournal, se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">4. Sikkerhedsevaluering</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;R&aring;varernes toksikologiske profil:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<B>Ingredienser (se pkt. 1)</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 1 &#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 2&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 3&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 4&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 5&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 6&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 7&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 8&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;ad 9&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;osv.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<B>Typisk anvendelse af f&aelig;rdigvaren: (se  \r\n\r\n vejledningen, kap. 2-4)</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;P&aring;f&oslash;ringsomr&aring;de</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;P&aring;f&oslash;ringsfrekvens</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<B>Sikkerheden for f&aelig;rdigvaren, konklusion:</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">5. Navn, adresse p&aring; den ansvarlige for  \r\n\r\n sikkerhedsevalueringen:</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;<A NAME=\"Kontrol1\"></A> CV:&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">6. U&oslash;nskede virkninger for  \r\n\r\n f&aelig;rdigvaren:</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;se bilag _____</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">7. Beviserne for f&aelig;rdigvarens  \r\n\r\n p&aring;st&aring;ede virkning:</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;se bilag _____</P>  \r\n\r\n</DIR>  \r\n\r\n</DIV><!-- End of \"Bilag 1\" -->  \r\n\r\n<A NAME=\"\"B2\"\"></A>\r\n\r\n<DIV CLASS=BILAG ID=\"B2\">  \r\n\r\n<HR width=70% align=center>  \r\n\r\n<B><FONT SIZE=4><P ALIGN=\"RIGHT\">Bilag 2</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Litteraturliste</P>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Forslag til opslagsv&aelig;rker, der vil v&aelig;re  \r\n\r\n egnede til indhentning af oplysninger til udarbejdelse af den generelle  \r\n\r\n toksikologiske profil for r&aring;varerne:</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Cosmetic Ingredient Review, CIR rapporter. The Cosmetic,  \r\n\r\n Toiletry, and Fragrance Association. L&oslash;bende udgivelser.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Martindale, The Extra Pharmacopoeia, 31. ed. London: Royal  \r\n\r\n Pharmaceutical Society, 1996.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">International Cosmetic Ingredient Dictionary, 7.ed.  \r\n\r\n Washington DC, The Cosmetic, Toiletry, and Fragrance Association, 1997.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">de Groot, A.C., Weyland, J.W., Nater, J.P.: Unwanted  \r\n\r\n Effects of Cosmetics and Drugs used in Dermatology, 3.ed. Amsterdam: Elsevier  \r\n\r\n Science B.V.,1994.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Richardson, M.L. and Gangolli, S.: The Dictionary of  \r\n\r\n Substances and their Effects. Royal Society of Chemistry 1992-1994.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Fisher, A.A.: Contact Dermatitis, 3.ed.Philadelphia: Lea  \r\n\r\n &amp; Febiger, 1986.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Databaser, der vil v&aelig;re egnede:</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P><DIR>  \r\n\r\n<DIR>  \r\n\r\n<DIR>  \r\n\r\n<DIR>  \r\n\r\n<DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">MEDLINE</B>&#9;(Medical Literature Analysis and  \r\n\r\n Retrieval System (MEDLARS&reg;) on-line)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;National Library of Medicine (NLM)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Medlars Management Section</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;8600 Rockville Pike</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Bethesda, MD 20894, USA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;MEDLINE corresponds to three print indexes: Index  \r\n\r\n Medicus&trade;, Index to Dental Literature, and International Nursing  \r\n\r\n Index.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">TOXLINE</B>&#9;(Toxicology Information On-line)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;National Library of Medicine (NLM)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Specialized Information Services</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;8600 Rockville Pike</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Bethesda, MD 20894, USA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;TOXLINE comprises several individual sub-files  \r\n\r\n supplied by different producers.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">RTECS</B>&#9;(Registry of Toxic Effects of Chemical  \r\n\r\n Substance)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;RTECS is built and maintained by the National  \r\n\r\n Institute for Occupational Safety and Health (NIOSH) of the Department of  \r\n\r\n Health and Human Services of the United States of America</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;4676 Colombia Parkway, Cincinnati</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Ohio 45226, USA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">EMBASE</B> &#9;(Excerpta Medica Database)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Elsevier Science B.V.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Secondary Publishing Division</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Molenwerf 1</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;NL-1014 AG Amsterdam</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;EMBASE corresponds to the printed Excerpta Medica  \r\n\r\n Sections.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">BIOSIS PREVIEWS</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher: BIOSIS</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;2100 Arch Street</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Philadelphia, PA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;USA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;BIOSIS PREVIEWS&reg; contains citations from  \r\n\r\n Biological Abstracts&reg; (BA), Biological Abstracts/RRM&reg; (Reports,  \r\n\r\n Reviews, Meetings (BA/RRM), and BioResearch Index&reg; (BioI), the major  \r\n\r\n publications of BIOSIS&reg; (BA/RRM is the successor to BioI beginning in  \r\n\r\n 1980).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">IPA</B> &#9;(International Pharmaceutical  \r\n\r\n Abstracts)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher: American Society of Hospital  \r\n\r\n Pharmacists</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;7272 Wisconsin Avenue </P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Bethesda, MD 20814</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;USA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;and</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;American Society of Health-System Pharmacists</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Dr. Dwight R. Tousignaut or Kate Gibbons</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Database Services</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;7272 Wisconsin Avenue</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Bethesda, MD 20814</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">CHEMICAL ABSTRACTS</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Chemical Abstracts Service</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;2540 Olentangy River Road</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;P.O. Box 3012</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Columbus, OH 43210-0012</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;U.S.A.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;The database corresponds to the printed version.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">SCISEARCH</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Producer / publisher:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Institute for Scientific Information (ISI)</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;3501 Market Street</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;Philadelphia, PA 19104</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;USA</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&#9;SciSearch corresponds to the printed Science Citation  \r\n\r\n Index&reg; (SCI&reg;) and contains additional records from the Current  \r\n\r\n Contents&reg; series of publications that are not included in the print  \r\n\r\n version of SCI.</P>  \r\n\r\n</DIR>  \r\n\r\n</DIR>  \r\n\r\n</DIR>  \r\n\r\n</DIR>  \r\n\r\n</DIR>  \r\n\r\n</DIV><!-- End of \"Bilag 2\" -->  \r\n\r\n<A NAME=\"\"B3\"\"></A>\r\n\r\n<DIV CLASS=BILAG ID=\"B3\">  \r\n\r\n<HR width=70% align=center>  \r\n\r\n<B><FONT SIZE=4><P ALIGN=\"RIGHT\">Bilag 3</P>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Synopsis prepared by Prof. J&oslash;rgen Serup. M.D.,  \r\n\r\n Ph.D.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ingeborgvej 42, DK-2900 Hellerup, Denmark</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><FONT SIZE=6><P ALIGN=\"CENTER\">Synopsis of</P>  \r\n\r\n<P ALIGN=\"CENTER\"></P>  \r\n\r\n<P ALIGN=\"CENTER\">efficacy testing of cosmetic products</P>  \r\n\r\n</B>  \r\n\r\n</FONT>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"CENTER\">Danish Environmental Protection Agency</P>  \r\n\r\n<P ALIGN=\"CENTER\">Ministry of Environment and Energy</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"CENTER\">June 28, 2000</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Contents</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Introduction&#9; 3</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Aim&#9; 3</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Documentation of biomedical efficacy in</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">perspective&#9; 3</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The Declaration of Helsinki and protection</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">of subjects participating in trials&#9; 4</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The ICH tripartite guideline for good</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">chemical practice&#9; 5</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Ambition level for substantiating the</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">efficacy of cosmetic products&#9; 6</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Colipa <I>Guidelines for the evaluation of the</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">efficacy of cosmetic products</I>&#9; 6</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Study objectives and reported endpoints in</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">trials documenting the efficacy of</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">cosmetic products&#9; 6</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Instrumental evaluation of efficacy in</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">humans using non-invasive techniques&#9; 7</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Information on raw materials and</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">ingredients in substantiating the efficacy</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">of a final product&#9; 8</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">In vitro efficacy models&#9; 8</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Reference to literature&#9; 9</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">General principles and conclusion&#9; 9</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Notes on design and critical elements in</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">human testing of the efficacy of cosmetic</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">products&#9; 9</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">References&#9; 13</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Annex: terminology&#9; 13</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Introduction</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Council Directive 93/35/EEC of 14 June 1993 (the Cosmetics  \r\n\r\n Directive) (1), which has been implemented in Denmark, states in Article 7a,  \r\n\r\n 1.g:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The manufacturer or his agent or the person to whose order  \r\n\r\n a cosmetic product is manufactured or the person responsible for placing an  \r\n\r\n imported cosmetic product on the Community market shall for control purposes  \r\n\r\n keep the following information readily accessible to the competent  \r\n\r\n authorities of the Member State concerned at the address specified on the  \r\n\r\n label in accordance with Article 6 (1) (a):</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">g) proof of the effect claimed for the cosmetic product,  \r\n\r\n where justified by the nature of the effect or product.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The Cosmetics Directive defines the nature of the effects  \r\n\r\n of cosmetic products in Article 1, 1<FONT FACE=\"Times\" SIZE=3>:</P>  \r\n\r\n</FONT>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A &quot;cosmetic product&quot; shall mean any substance or  \r\n\r\n preparation intended to be placed in contact with the various external parts  \r\n\r\n of the human body (epidermis, hair system, nails, lips and external genital  \r\n\r\n organs) or with the teeth and the mucous membranes of the oral cavity with a  \r\n\r\n view exclusively or mainly to cleaning them, perfuming them, changing their  \r\n\r\n appearance and/or correcting body odours and/or protecting them or keeping  \r\n\r\n them in good condition.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Thus, depending on the nature and claimed effect(s) of the  \r\n\r\n product, documentation must be available, organized and presented swiftly to  \r\n\r\n competent authorities upon request to the responsible person or party. To be  \r\n\r\n appreciated fully, the documentation must directly address skin signs and  \r\n\r\n phenomena. Effects may include product-induced changes noticeable during  \r\n\r\n product use, protective effects of the product against various insults or  \r\n\r\n prophylactic effects in which untreated skin suffers damage or spontaneous  \r\n\r\n worsening, whereas treated skin remains unaffected or in a favourable  \r\n\r\n condition.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The European Union and the responsible authorities in  \r\n\r\n Denmark have not yet given any detailed guidance to the cosmetic industry on  \r\n\r\n the principles and methods for proper testing of efficacy of cosmetic  \r\n\r\n products, although the Scientific Committee on Cosmetic Products and Non-Food  \r\n\r\n Products intended for Consumers recently discussed and finally adopted basic  \r\n\r\n criteria for protocols and human testing of skin compatibility (2,3).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Aim</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The aim of this synopsis is to outline principles and  \r\n\r\n standards for efficacy testing of cosmetic products that can be used by both  \r\n\r\n responsible authorities in evaluating products and substantiation and the  \r\n\r\n industry in planning efficacy trials. The standards considered primarily  \r\n\r\n apply to the products that, due to their nature, need justification, but the  \r\n\r\n standards are generic and can be applied to cosmetic products in general.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The synopsis focuses on efficacy and does not address  \r\n\r\n safety issues.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Documentation of biomedical efficacy in perspective</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">In the history of science, efficacy documentation has  \r\n\r\n passed through phases of hypothetical consideration with deduction to  \r\n\r\n clinical situations, empirical experiments in animals and humans, studies of  \r\n\r\n cases and smaller groups, controlled trials and finally randomized controlled  \r\n\r\n trials, introduced more than 50 years ago and now universally accepted as the  \r\n\r\n gold standard for establishing truth in biomedical research with a clinical  \r\n\r\n objective. Further, according to international consensus, a single randomized  \r\n\r\n controlled trial may not suffice to establish a valid general conclusion, and  \r\n\r\n one or more confirmatory trials at additional centres may be required to  \r\n\r\n establish proof in a larger geographical territory. </P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Several systems have been described for evaluating quality  \r\n\r\n in research. These are condensed into a concept widely used under the name  \r\n\r\n evidence-based medicine<I>.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">According to evidence-based medicine, the validity of  \r\n\r\n trials may be ranked as follows (modified from Eccles et al. (4)):</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1a)&#9;evidence according to meta-analysis and systematic  \r\n\r\n review of a number of randomized controlled trials;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1b)&#9;evidence according to a minimum of one randomized  \r\n\r\n controlled trial;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2a)&#9;evidence according to a minimum of one controlled  \r\n\r\n trial with no randomization;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2b)&#9;evidence according to a directly relevant and valid  \r\n\r\n test method;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">3)&#9;evidence according to a valid test method of  \r\n\r\n indirect relevance, for example descriptive trial(s), correlations with other  \r\n\r\n groups and case-control studies; and</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">4)&#9;evidence according to case reports, small series,  \r\n\r\n expert statements and reviews.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The principles of evidence-based medicine are not limited  \r\n\r\n to evaluating therapies, whether medicinal or non-pharmaceutical, but are  \r\n\r\n also applied to diagnostic tests and prognostic and preventive studies and  \r\n\r\n are used to evaluate adverse reactions. The principles of evidence-based  \r\n\r\n medicine can be directly adopted as a system for evidence-based cosmetic  \r\n\r\n treatment<I>.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The need for systematic reviews in medicine has resulted  \r\n\r\n in the Cochrane Library (http://www.cochrane.co.uk), a huge database started  \r\n\r\n in 1992 by scientific reviewers based on the proposal of Professor Archie  \r\n\r\n Cochrane, with updated and systematic reviews primarily on therapies and  \r\n\r\n prophylaxis. Reviews are based exclusively on randomized controlled trials. A  \r\n\r\n Cochrane Skin Group was started in 1997  \r\n\r\n (http://www.nottingham.ac.uk/~muzd).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Thus, the randomized controlled trial is applicable to  \r\n\r\n many disciplines in biomedical research testing intervention in body, mind or  \r\n\r\n the environment, and this gold-standard design is directly applicable to the  \r\n\r\n documentation of cosmetic products as well as the development of  \r\n\r\n pharmaceutical products.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">The Declaration of Helsinki and protection of subjects  \r\n\r\n participating in trials</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The Declaration of Helsinki, adopted in 1964 by the 18th  \r\n\r\n World Medical Assembly, is an ethical recommendation guiding physicians in  \r\n\r\n biomedical research involving human subjects. It has been amended four times,  \r\n\r\n most recently in October 1996. The aim is to protect the integrity and  \r\n\r\n well-being of a subject in a biomedical study by ensuring proper risk  \r\n\r\n assessment and consideration of ethics by an independent review board. Study  \r\n\r\n participants must be well informed and grant written acceptance: informed  \r\n\r\n consent. The Declaration of Helsinki also addresses critical aspects of  \r\n\r\n research such as the study programme and conduct and the educational needs of  \r\n\r\n the research group.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Denmark adopted these principles in 1992 by adopting the  \r\n\r\n Act on a Scientific-Ethical Committee System and the Treatment of Biomedical  \r\n\r\n Research Projects. Such evaluation is required in every biomedical project  \r\n\r\n that includes humans. In Denmark a system with a number of regional ethics  \r\n\r\n committees and one central committee was established. The nature of a  \r\n\r\n cosmetic product, the claim and the study design may determine whether a  \r\n\r\n study is considered biomedical or not. To assess trials, ethics committees in  \r\n\r\n Denmark need a study protocol, a summary for laypeople, the written  \r\n\r\n information provided to subjects entering the study and an informed consent  \r\n\r\n form. The relevant committee can decide based on informal consultation that  \r\n\r\n the trial is not considered biomedical. Thus, a regional ethics committee  \r\n\r\n must be consulted before any human trial on a cosmetic product is  \r\n\r\n started.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Study data are often stored in electronic registers. The  \r\n\r\n Public Authorities  Registers (Consolidation) Act from 1978 applicable to a  \r\n\r\n broad range of electronic registers states that registers with personal  \r\n\r\n information in which the integrity of the registrants is at risk must be  \r\n\r\n approved by the Data Surveillance Authority, and the register used must be  \r\n\r\n considered secure. Council Directive 95/46/EC of 24 October 1995 (5), which  \r\n\r\n is not yet fully implemented in Denmark, also instituted such protection. In  \r\n\r\n Denmark, under the present rules and administrative practices, any study  \r\n\r\n registered electronically, or manually, containing personal information must  \r\n\r\n be protected under the auspices of the Data Surveillance Authority after  \r\n\r\n evaluation of the study and the security of the register. Thus, the Agency  \r\n\r\n must approve in writing every systematic study of cosmetic products in  \r\n\r\n Denmark. The Agency requests for the purpose of their assessment a brief  \r\n\r\n description of the trial with emphasis on register and data protection.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">The ICH tripartite guideline for good clinical  \r\n\r\n practice</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The ICH (International Conference on Harmonisation of  \r\n\r\n Technical Requirements for Registration of Pharmaceuticals for Human Use)  \r\n\r\n guideline for good clinical practice (ICH GCP), which was primarily developed  \r\n\r\n to document pharmaceutical products, is an international ethical and  \r\n\r\n scientific quality standard for designing, conducting, recording and  \r\n\r\n reporting trials that involve the participation of human subjects (6).  \r\n\r\n Compliance with this now internationally implemented standard provides public  \r\n\r\n assurance that the rights, safety and well-being of trial subjects are  \r\n\r\n protected, consistent with the principles that have their origin in the  \r\n\r\n Declaration of Helsinki and that the clinical trial data are credible. The  \r\n\r\n declared objective of the ICH GCP Guideline is to provide a unified standard  \r\n\r\n for the European Union, Japan and the United States as a basis for mutual  \r\n\r\n recognition of clinical data by the regulatory authorities in those three  \r\n\r\n jurisdictions.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The ICH GCP guideline is based on the following general  \r\n\r\n principles.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Clinical trials should be conducted in accordance with the ethical  \r\n\r\n principles that have their origin in the Declaration of Helsinki, including  \r\n\r\n informed consent and confidentiality covering any record or document.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Trials should be scientifically sound and described in a clear, detailed  \r\n\r\n protocol, and the anticipated benefits should justify the anticipated  \r\n\r\n risks.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Trials should be conducted in compliance with a protocol that has  \r\n\r\n received prior approval by an ethics committee.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;A physician or dentist should always be responsible for medical decisions  \r\n\r\n and the medical care given.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Test personnel should be adequately educated and trained.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;All clinical trial information should be recorded, handled and stored in  \r\n\r\n a way that allows it to be accurately reported, interpreted and verified.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Investigational products should be manufactured, handled and stored  \r\n\r\n according to good manufacturing practice and used according to the  \r\n\r\n protocol.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Systems with procedures that assure the quality of every aspect of the  \r\n\r\n trial should be implemented.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The randomized controlled trial in humans is essential in  \r\n\r\n the ICH GCP. The pharmaceutical industry swiftly adopted ICH GCP during 1997,  \r\n\r\n allocated the necessary resources and established elaborate in-house systems  \r\n\r\n with standard operating procedures, quality assurance and quality control. A  \r\n\r\n major educational effort has been undertaken and resulted in an enthusiastic  \r\n\r\n GCP culture in which things are not underdone. Investigators, project  \r\n\r\n leaders, monitors and quality control officers have refined test practices  \r\n\r\n and helped GCP conduct in several ways. The implementation and maintenance of  \r\n\r\n the guideline has become a continuing process with constant refinements and  \r\n\r\n educational activities.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The GCP guideline is directly applicable to the efficacy  \r\n\r\n testing of cosmetic products.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Ambition level for substantiating the efficacy of  \r\n\r\n cosmetic products</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The ICH GCP guideline is directly applicable to trials of  \r\n\r\n cosmetic products on humans. This offers responsible authorities and the  \r\n\r\n product users the highest level of certainty that claims made for cosmetic  \r\n\r\n products hold true. The pharmaceutical industry has demonstrated that GCP  \r\n\r\n systems can be practised to a high degree of sophistication, but establishing  \r\n\r\n and maintaining GCP are costly. The pharmaceutical industry has a long  \r\n\r\n tradition of clinical trials based on various national GCP systems introduced  \r\n\r\n some years ago. This platform was important in the successful introduction of  \r\n\r\n ICH GCP during 1997. The same platform is not present in the cosmetic  \r\n\r\n industry, which additionally may have a different company profile, with few  \r\n\r\n large and numerous small and medium-sized enterprises. Thus, an advanced  \r\n\r\n system such as ICH GCP that ensures the credibility of trials in humans is  \r\n\r\n not yet fully and immediately applicable to cosmetic product efficacy  \r\n\r\n testing. Nevertheless, essential elements can be adopted.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">The Colipa Guidelines for the evaluation of the  \r\n\r\n efficacy of cosmetic products</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Colipa (the European Cosmetic Toiletry and Perfumery  \r\n\r\n Association) represents European manufacturers of cosmetic products. In  \r\n\r\n August 1997, Colipa published <I>Guidelines for the evaluation of the  \r\n\r\n efficacy of cosmetic products</I>, with general information and some  \r\n\r\n statements about human testing, instrumental evaluation and non-human models  \r\n\r\n (7). The guidelines list essentials such as the need for a formal protocol, a  \r\n\r\n responsible person, the objective and relevance of the trial, schedule,  \r\n\r\n statistics and recording and interpreting the results. Nevertheless, the  \r\n\r\n value of the guidelines is restricted by the lack of detailed information and  \r\n\r\n a lack of opinion about the essential elements needed for a trial or  \r\n\r\n documentation to be conclusive. It can only serve as a loose framework to  \r\n\r\n inspire cosmetic scientists. The guidelines accept studies carried out on  \r\n\r\n non-human models and published data on ingredients as documentation of the  \r\n\r\n final product.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The industry probably has a number of in-house standards  \r\n\r\n for efficacy testing in a company context, but such standards, which are  \r\n\r\n likely to be detailed, have typically not reached the public domain. In-house  \r\n\r\n standards may be relevant for authorities in assessing individual products if  \r\n\r\n they are made transparent.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Study objectives and reported endpoints in trials  \r\n\r\n documenting the efficacy of cosmetic products</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A logical prerequisite for substantiation of a claim in a  \r\n\r\n trial is that the claim be identical to a defined endpoint in a trial.  \r\n\r\n Studies may have one primary endpoint covering the main claim of the product  \r\n\r\n and a number of secondary endpoints. People use cosmetic products to achieve  \r\n\r\n cutaneous effects that they can see using the naked eye, feel with their  \r\n\r\n fingers or smell. Endpoints assessed by users themselves or a representative  \r\n\r\n panel of observers have first-line relevance. In-use assessment by specially  \r\n\r\n trained evaluators may produce more precise and reproducible information on a  \r\n\r\n smaller sample. Scoring scales and visual analogue scales are typically used  \r\n\r\n in such assessment. Scores and scales must display the full range of expected  \r\n\r\n effects in a reasonably balanced way.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Claims as understood by lay consumers may easily differ  \r\n\r\n from claims worded on package inserts and other written material and defined  \r\n\r\n endpoints in trials, and it must be critically considered that there be no  \r\n\r\n deviation in meaning or appreciation from the trial endpoint to the claim  \r\n\r\n understood by the consumer in real-world situations.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Surrogate endpoints are study objectives that provide  \r\n\r\n indirect evidence about the postulated effect of the product on a user.  \r\n\r\n Surrogates may be quantitative and measurable with very high precision and  \r\n\r\n allow very detailed and reproducible information on a small sample and may  \r\n\r\n therefore be more operable than direct user endpoints. Surrogates may include  \r\n\r\n skin structure and function variables measured with noninvasive instrumental  \r\n\r\n methods, chemical and physical properties, and others. However, the validity  \r\n\r\n of a surrogate endpoint depends entirely on its relevance to the in-use  \r\n\r\n situation under real conditions.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The outcome of in vitro testing and arguments based on  \r\n\r\n product composition clearly represent non-human data distant from real  \r\n\r\n endpoints in a user situation.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Instrumental evaluation of efficacy in humans using  \r\n\r\n non-invasive techniques</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Several biophysical and computerized methods for  \r\n\r\n objectively characterizing skin structure and function without invading the  \r\n\r\n skin or interfering with the function measured have been developed in recent  \r\n\r\n decades. The techniques characterize: surface properties such as scaling and  \r\n\r\n dryness, colour and pigmentation (colorimetry), relief and wrinkles  \r\n\r\n (profilometry); skin structures (high frequency ultrasound, confocal  \r\n\r\n microscopy); functions such as blood flow (laser Doppler scanning), surface  \r\n\r\n lipids and sebum production (sebumetry), water evaporation and sweating  \r\n\r\n (evaporimetry); and other parameters. The methods typically measure selected  \r\n\r\n properties dependent on the measuring principle and not overall endpoints as  \r\n\r\n normally appreciated by product users in their self-assessment. Many of the  \r\n\r\n techniques are highly precise and accurate<B>, </B>and significant changes  \r\n\r\n may be demonstrable in a limited number of individuals. Hydration, blood  \r\n\r\n flow, skin elasticity, skin thickness and dermis structure are examples of  \r\n\r\n parameters that can be quantified noninvasively using techniques but only  \r\n\r\n assessed with difficulty clinically. Various methods have been formally  \r\n\r\n validated in published guidelines describing typical variables such as  \r\n\r\n measuring conditions and needs for preconditioning of the test individual,  \r\n\r\n laboratory room conditions, instrumental variation and calibration.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The critical factors in noninvasive techniques are as  \r\n\r\n follows.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;The parameter measured must be relevant to the effect of the product and  \r\n\r\n the claim.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;The laboratory facility must be adequate.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Staff must be specially educated and trained in the test method and  \r\n\r\n procedure.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Instruments and measurement must be described in a standard operating  \r\n\r\n procedure, and existing guidelines should be followed.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;The instrument used must be calibrated and stable and remain so during  \r\n\r\n the trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;Test subjects must be well informed and adequately preconditioned before  \r\n\r\n measurement.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;The recorded data and samples taken must be properly labelled, handled  \r\n\r\n and processed.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The relevance of the parameter measured, direct or  \r\n\r\n surrogate, is an important issue that requires special argument in a trial.  \r\n\r\n Because of the nature of the techniques, a narrow feature is typically  \r\n\r\n measured under special conditions (such as magnification, amplification or  \r\n\r\n filtering) and with high precision.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">When noninvasive techniques are being used to substantiate  \r\n\r\n the final product as a stand-alone test, the researcher and the sponsoring  \r\n\r\n company have a special obligation to argue the relevance of the test relative  \r\n\r\n to the effect, claim and use of the final product and the precision and  \r\n\r\n validity of the instrument and the test procedure actually used in the  \r\n\r\n trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Thus, noninvasive techniques may measure endpoints in the  \r\n\r\n documentation of efficacy of final products in trials in humans and even  \r\n\r\n evaluate the endpoint as a stand-alone test if the test can be argued to be  \r\n\r\n relevant and valid in relation to the effect and the product claim. The  \r\n\r\n format of the basic design must be a randomized controlled trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The standardization group on noninvasive methods of the  \r\n\r\n European Society of Contact Dermatitis published in the journal <I>Contact  \r\n\r\n Dermatitis</I> various formal guidelines on instrumental evaluation of skin:  \r\n\r\n transepidermal water loss, colour and blood flow. The <I>Handbook of  \r\n\r\n non-invasive methods and the skin</I> provides detailed information on  \r\n\r\n noninvasive methods used for efficacy documentation (8). An informal group  \r\n\r\n named EEMCO (European Group for Efficacy Measurements on Cosmetics and other  \r\n\r\n Topical Products) including industry representatives published various  \r\n\r\n introductory reviews on measuring techniques such as colorimetry and skin  \r\n\r\n elasticity and a guidance paper on clinical evaluation of dryness, which can  \r\n\r\n be used in validating instrumental methods for measuring skin hydration  \r\n\r\n (9).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Information on raw materials and ingredients in  \r\n\r\n substantiating the efficacy of a final product</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The efficacy of a final product may refer to a single  \r\n\r\n ingredient, a number of ingredients acting together, the base as such or the  \r\n\r\n complete product. The physicochemical properties and the purity of  \r\n\r\n ingredients, the supplier and the supplied batch of raw material and the  \r\n\r\n whole manufacturing process are known variables influencing the final  \r\n\r\n product. The efficacy of a final product cannot, in general, be proven  \r\n\r\n directly from the recipe listing individual ingredients for the reasons  \r\n\r\n mentioned above, although efficacy may be predicted and argued with some  \r\n\r\n precision depending on the recipe and the background knowledge. Exceptions  \r\n\r\n may occur when, for example, a chemically well characterized ingredient  \r\n\r\n exerts a known, strong effect and is also evaluated with respect to  \r\n\r\n requirements in a formulation and found uncomplicated to formulate or  \r\n\r\n relatively independent of the vehicle. Essentials such as the relationship  \r\n\r\n between dose and concentration or dose and effect, optimum pH and ingredient  \r\n\r\n stability must be known. Peeling agents, acting as corrosive irritants, may  \r\n\r\n represent such an exception, although efficacy always varies somewhat  \r\n\r\n according to vehicle composition and properties.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Thus, strong arguments are needed to substantiate the  \r\n\r\n efficacy of a final product based on information about the recipe and  \r\n\r\n individual ingredients, and proof of efficacy of final products should, with  \r\n\r\n exceptions, depend on the outcome of relevant testing in humans with  \r\n\r\n application of the product according to anticipated use.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Minor modifications of formulations for which claims have  \r\n\r\n already been established and efficacy proven are a special issue. Proof of  \r\n\r\n efficacy may be maintained if arguments are presented that the change is  \r\n\r\n unimportant for the efficacy endpoint.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Products manufactured using the same recipe by different  \r\n\r\n companies or the same company in different plants are not automatically  \r\n\r\n biologically equivalent. Chemical and physical characterization of the  \r\n\r\n original product and the copy may suffice for documenting equivalence, and  \r\n\r\n this may be backed up by demonstrating similar penetration of the product or  \r\n\r\n essential ingredients into artificial or human skin. A range of sophisticated  \r\n\r\n techniques are known from skin pharmacology.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Efficacy testing directly in humans remains the ultimate  \r\n\r\n test.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">In vitro efficacy models</P>  \r\n\r\n</B>  \r\n\r\n<P>A number of in vitro efficacy models exist. These models can be useful  \r\n\r\n tools in the research and development of a product, for example for the  \r\n\r\n purposes of selecting the best ingredient among various options, for  \r\n\r\n estimating the relationship between dose and efficacy in the laboratory and  \r\n\r\n for other purposes that lead to a best-fit product candidate that is ready to  \r\n\r\n be tested in humans. Nevertheless, in vitro testing can only provide a rough  \r\n\r\n estimate and only add marginal information about a final product unless the  \r\n\r\n test in a proper document has been validated in relation to the anticipated  \r\n\r\n human in-use situation and deemed suitable for substantiating the efficacy of  \r\n\r\n such a final product with respect to the specified effect.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Thus, in vitro tests are important research tools.  \r\n\r\n Nevertheless, these tools are generally not acceptable in documenting the  \r\n\r\n efficacy of final products unless their validity with regard to user  \r\n\r\n relevance and the claim of the product is documented.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Reference to literature</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Reference to literature is important in explaining the  \r\n\r\n background of a product, discussing the findings of a test and determining  \r\n\r\n the validity of a test method. Thus, critical review and reference to  \r\n\r\n literature is an important instrument in the process of substantiating the  \r\n\r\n efficacy of cosmetic products in various ways but in itself never comprises  \r\n\r\n proof replacing a randomized controlled trial. Literature remains indicative.  \r\n\r\n Referenced literature must be in depth and complete and at an academic level,  \r\n\r\n carefully selected on rational grounds and presented in a non-promotional way  \r\n\r\n with balanced information about advantages and disadvantages.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">General principles and conclusion</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Any claim that must be verified based on the nature of the  \r\n\r\n product and that can be measured must be documented in a randomized  \r\n\r\n controlled trial in humans who are a representative sample of the anticipated  \r\n\r\n user group.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Trials in humans must be conducted in accordance with the  \r\n\r\n intention and main principles of the ICH harmonized tripartite guideline for  \r\n\r\n good clinical practice, which gives international ethical and scientific  \r\n\r\n quality standards for designing, recording and reporting trials that involve  \r\n\r\n the participation of human subjects, but strict adherence to this guideline  \r\n\r\n is not realistic and therefore not felt mandatory in documenting the efficacy  \r\n\r\n of cosmetic products.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Documentation must be based on testing of the final  \r\n\r\n product identical to the product to be marketed.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Claims must be identical to endpoints measured in  \r\n\r\n trials.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">User self-assessment and evaluation of user-relevant  \r\n\r\n effects by panellists or trained observers are gold-standard endpoints in  \r\n\r\n trials. Endpoints representing skin structure and function measured by  \r\n\r\n biophysical methods are also acceptable as endpoints if the methods are  \r\n\r\n validated and demonstrated to be precise and if results are shown to be  \r\n\r\n directly relevant to the claimed effect in users.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Data on raw materials and ingredients in a product, pure  \r\n\r\n laboratory testing and reference to the literature are generally informative  \r\n\r\n but not acceptable for documenting the efficacy of a final cosmetic  \r\n\r\n product.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Documentation must always be scientifically sound and  \r\n\r\n relevant to the claim and the intended use of the product.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The documentation must not make claims or be laid out is  \r\n\r\n such a way that various statements dilute, scatter or modify or deviate in  \r\n\r\n opinion or impression from what was actually documented through  \r\n\r\n experimentation.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Notes on design and critical elements in human testing  \r\n\r\n of the efficacy of cosmetic products</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">As stated above, the elaborate ICH GCP system for human  \r\n\r\n testing is not considered to be realistic for the cosmetic industry at this  \r\n\r\n time. Elements that may be sought implemented immediately in efficacy testing  \r\n\r\n of cosmetic products are addressed in the following.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Evidence-based documentation of the efficacy of  \r\n\r\n cosmetic products</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">For cosmetic products, as a general rule, the acceptable  \r\n\r\n rank of evidence should be category 1: a minimum of one well-conducted  \r\n\r\n randomized controlled trial. Category 2a may also be acceptable if proper  \r\n\r\n blinding and randomization cannot be conducted for technical or ethical  \r\n\r\n reasons, for example in the documentation of a peeling agent when visible  \r\n\r\n irritation is closely linked with efficacy. Category 2b is acceptable if the  \r\n\r\n test method actually used is validated and its user relevance documented,  \r\n\r\n including determination of the minimum user-relevant difference.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Ethical testing</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The spirit of the Declaration of Helsinki would indicate  \r\n\r\n that written information and informed consent should be standard in cosmetic  \r\n\r\n product testing, although it may not be formally required depending on  \r\n\r\n evaluation of a particular trial by a local review board. In Denmark the Data  \r\n\r\n Surveillance Authority must approve a study. Ethics and testing of cosmetic  \r\n\r\n products were addressed previously in this synopsis.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Sponsor and dossier on efficacy</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A sponsoring company, institution or person should be  \r\n\r\n assigned to take the main responsibility, including liability, for test  \r\n\r\n subjects. This sponsor should organize a dossier on efficacy documentation,  \r\n\r\n properly secured and with all relevant trial material readily available.  \r\n\r\n British Standard BS 5454:2000 (10) addresses storage conditions and secure  \r\n\r\n storage of source data and documents.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Who can be accepted as responsible for cosmetic product  \r\n\r\n testing?</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Cosmetic products are not medicines and differ formally  \r\n\r\n and by their nature and effect-to-safety ratio from medicinal products, and a  \r\n\r\n researcher with documented relevant education and qualification can therefore  \r\n\r\n take responsibility for a test and a research team. Qualifications can be  \r\n\r\n documented in a curriculum vitae and an educational record. Supervision by a  \r\n\r\n physician is not felt necessary unless a medical problem arises or is likely  \r\n\r\n to arise.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Trial protocol</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A detailed trial protocol must be prepared before the  \r\n\r\n trial is conducted and properly dated and signed off by the investigator and  \r\n\r\n the sponsor.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Trial design</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A randomized controlled trial in humans is the gold  \r\n\r\n standard to be used whenever applicable, independent of the trial endpoint  \r\n\r\n and the method of recording.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Comparator product</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A placebo control should be chosen whenever possible. When  \r\n\r\n efficacy is supposed to be related to a single or a few ingredients that can  \r\n\r\n be omitted in the formulation without changing its physical properties and  \r\n\r\n odour, such a placebo formulation without active ingredient(s) is preferable.  \r\n\r\n Special attention should be focused on the need for similarity between test  \r\n\r\n product and comparator with respect to fragrance and odour, viscosity and  \r\n\r\n colour. It may sometimes be impossible to identify or omit active  \r\n\r\n ingredients. A marketed, neutral product claimed to be a moisturizer or a  \r\n\r\n cream base or an otherwise relevant but inert marketed product similar to the  \r\n\r\n test product with respect to odour, viscosity and colour may be chosen as the  \r\n\r\n comparator. The relevant fragrance may be added to the comparator product, if  \r\n\r\n necessary, to approximate similarity. An experimental formulation may also be  \r\n\r\n used, but this must be formulated as an inert reference without any  \r\n\r\n anticipated endpoint effect, positive or negative, that could invalidate it  \r\n\r\n as a comparator formulation. The lack of difference between investigational  \r\n\r\n and comparator products in physical properties may be documented in the  \r\n\r\n laboratory and confirmed in a pilot study in humans that also addresses  \r\n\r\n odour.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Production of test product</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Test products should be produced under quality conditions  \r\n\r\n according to the Council of Europe Guidelines for Good Manufacturing Practice  \r\n\r\n of Cosmetic Products (GMPC) from 1995 (11), ideally after scale up in the  \r\n\r\n production line used for the final production.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Calculation of sample size to estimate the size of the  \r\n\r\n groups needed</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The state-of-the-art requirement in trials is a  \r\n\r\n statistical power calculation by a statistician. True differences are  \r\n\r\n overlooked if groups are too small, especially if the expected endpoint  \r\n\r\n difference among groups compared is minor and the variation in the measured  \r\n\r\n endpoint is major. It is in the interest of the sponsor that test groups not  \r\n\r\n be too small and that true effect as a basis for claims not be overlooked.  \r\n\r\n Groups smaller than 20 are not usually considered convincing in  \r\n\r\n substantiating cosmetic products that normally induce minor changes, in  \r\n\r\n contrast to medicinal products used for skin diseases. Depending on the study  \r\n\r\n and products tested, major statistically significant differences obtained in  \r\n\r\n groups smaller than 20 might arouse suspicion that the study suffers from a  \r\n\r\n major bias or imperfection of blinding, for example, related to the selection  \r\n\r\n of test subjects, the cosmetic products applied or the measuring methods.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Selecting test subjects according to defined inclusion  \r\n\r\n and exclusion criteria</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Study groups must realistically represent the range of  \r\n\r\n anticipated users of the product with respect to such factors as sex, age and  \r\n\r\n social class. Participants with skin diseases or sun-damaged skin may  \r\n\r\n invalidate the results. Positive (inclusion) and negative (exclusion or  \r\n\r\n non-inclusion) criteria should be defined in the trial protocol.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Quantitative and qualitative endpoints and claims:  \r\n\r\n examples</P><DIR>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;Quantitative endpoints and claims can be measured  \r\n\r\n and must be documented by a relevant method from natural sciences.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Example 1. </I>A product is claimed to increase hair  \r\n\r\n growth. This can be documented by serial standard photographs and blinded  \r\n\r\n scoring by trained evaluators, by trichograms that measure the number of  \r\n\r\n hairs per unit of area, by trichograms with measurement of growth rate or by  \r\n\r\n gravimetric determination of hair growth in a defined area. The user-relevant  \r\n\r\n differences have to be known in advance.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Example 2.</I> A product is claimed to reduce the  \r\n\r\n number and size of wrinkles. This can be documented by the user s and  \r\n\r\n evaluator s scoring or assessment on a visual analogue scale, by serial  \r\n\r\n standard photos and blinded scoring or by a skin surface replica and  \r\n\r\n profilometry using predetermined limits for user relevance. A difference in  \r\n\r\n skin microrelief determined on a skin surface replica under magnification and  \r\n\r\n special lighting is not automatically relevant to the user.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Qualitative endpoints and claims may be documented  \r\n\r\n by a relevant method known from psychology, if this is considered relevant  \r\n\r\n for a cosmetic product.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Example 3.</I> A product is claimed to increase sexual  \r\n\r\n attractiveness. This can be tested in a relevant test panel.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Example 4.</I> A product is claimed to make the user  \r\n\r\n feel younger. This can be tested in a relevant group of potential users  \r\n\r\n giving their self-assessment.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Qualitative claims for cosmetic products are common and  \r\n\r\n may be regarded as artistic and therefore not misleading, and special testing  \r\n\r\n may not be felt necessary.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Endpoints and measuring methods</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The protocol must define the endpoints to be measured and  \r\n\r\n position them as primary and secondary. The relevance of endpoints must be  \r\n\r\n discussed and argued. Special consideration is obligatory if the endpoint is  \r\n\r\n a surrogate. Measuring methods may be categorized as follows:</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P><DIR>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;<I>User self-assessment</I>. The user herself or himself evaluates the  \r\n\r\n skin structure and function or the subjective feeling defined in the protocol  \r\n\r\n that is expected to be influenced by the treatment and evaluated according to  \r\n\r\n a scoring scheme or a visual analogue scale.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;<I>Examination by a panel of evaluators</I>. Observers with a defined  \r\n\r\n background perform the evaluation as objectively as possible according to a  \r\n\r\n defined system (see above).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;<I>Instrumental measurement</I>. A measuring device is used following its  \r\n\r\n validation before the trial according to a standard operating procedure  \r\n\r\n describing measuring conditions and variables. The operator must be educated  \r\n\r\n and trained in the use of the instrument.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"><FONT FACE=\"Symbol\">&#183;</FONT>  \r\n\r\n &#9;<I>According to samples</I>. Samples such as scales and surface biopsies  \r\n\r\n may be taken for additional evaluation according to the protocol.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Statistical methods and blinding</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The protocol must outline the method of randomization,  \r\n\r\n data processing and statistical methods to be used for data analysis. The  \r\n\r\n analysed sample must include all treated subjects according to the  \r\n\r\n intention-to-treat principle, and drop-outs should be reported in detail.  \r\n\r\n Coding must be used vigorously as an instrument in blinding the trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Unblinding and reporting</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The subjects should not be unblinded until the data are  \r\n\r\n checked for completeness and correctness, the database formally locked and  \r\n\r\n the statistical calculation concluded. Finally, the study<I> </I>should be  \r\n\r\n disseminated in a written report with all study data tabulated in an annex to  \r\n\r\n clarify any discrepancy or incorrectness that might be considered in the  \r\n\r\n future. It is crucial for the credibility of a trial that the original  \r\n\r\n results can be inspected and recalculated.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Archiving</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The source data, source documents and other relevant  \r\n\r\n documentation are archived. Archiving must be organized and secure (10). It  \r\n\r\n must be possible at any time to verify that the subjects really existed, that  \r\n\r\n the trial really took place etc. and that there is no suspicion of fraud.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Computer validation</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The computer software used should be specified and  \r\n\r\n databases and data operations should be validated. The US Food and Drug  \r\n\r\n Administration prepared guidance for industry on this (12).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Study conduct and monitoring</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Study conduct can be improved if recorded details are  \r\n\r\n pencilled in case report forms and dated and signed by a responsible person,  \r\n\r\n and if the correctness of recordings is checked by an impartial person: a  \r\n\r\n monitor not directly involved with the recording. It should be ensured that  \r\n\r\n the study complies with the protocol. Notes for the file and protocol  \r\n\r\n amendments must be made if changes are introduced.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Quality assurance, quality control and auditing</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The credibility of a study depends on control of the trial  \r\n\r\n by a monitor while it is ongoing and on independent quality control and  \r\n\r\n auditing by quality control inspectors. They must check the formal status of  \r\n\r\n the trial including legal approvals and consent form, the test facility and  \r\n\r\n staffs involved, the investigational and comparator products and other  \r\n\r\n factors. They prepare a written report on compliance and deviations in study  \r\n\r\n conduct related to the protocol, standard operating procedures etc. Auditing  \r\n\r\n must include a check of relevant source data and documents such as case  \r\n\r\n report forms and their archiving. Auditing is also necessary to ensure that  \r\n\r\n procedures for blinding and randomization are not invalidated and that fraud  \r\n\r\n is beyond suspicion.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Adverse events and reactions</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Adverse events and reactions should be systematically  \r\n\r\n looked for and registered, and a physician should be contacted if health  \r\n\r\n concern arises.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">References</P><DIR>  \r\n\r\n<DIR>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">1.&#9;Council Directive 93/35/EEC of 14 June 1993 amending  \r\n\r\n for the sixth time Directive 76/768/EEC on the approximation of the laws of  \r\n\r\n the Member States relating to cosmetic products  \r\n\r\n (http://europa.eu.int/eur-lex/en/lif/dat/1993/en_393L0035.html). <I>Official  \r\n\r\n Journal of the European Communities</I> 1993;L151(23/6):32 37 (accessed 27  \r\n\r\n June 2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">2.&#9;Scientific Committee on Cosmetics and Non-food  \r\n\r\n Products intended for Consumers. <I>Opinion concerning guidelines on the use  \r\n\r\n of human volunteers in compatibility testing of finished cosmetic products  \r\n\r\n adopted by the Scientific Committee on Cosmetics and Non-food Products  \r\n\r\n intended for Consumers during the plenary session of 23 June 1999</I>  \r\n\r\n (http://europe.eu.int/ comm/dg24/health/sc/sccp/out87_en.html). Brussels,  \r\n\r\n European Commission, 23 June 1999 (accessed 27 June 2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">3.&#9;Scientific Committee on Cosmetic Products and  \r\n\r\n Non-food Products intended for Consumers. <I>The Scientific Committee on  \r\n\r\n Cosmetic Products and Non-food Products intended for Consumers opinion  \r\n\r\n concerning basic criteria of the protocols for the skin compatibility testing  \r\n\r\n of potentially cutaneous irritant cosmetic ingredients or mixtures of  \r\n\r\n ingredients on human volunteers</I>  \r\n\r\n (http://europa.eu.int/comm/dg24/health/sc/sccp/out101_en.pdf). Brussels,  \r\n\r\n European Commission, 8 December 1999 (accessed 27 June 2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">4.&#9;Eccles M, Freemantle N, Mason J. North of England  \r\n\r\n evidence based guidelines development project: methods of developing  \r\n\r\n guidelines for efficient drug use in primary care. <I>British Medical  \r\n\r\n Journal</I> 1998;316:1232 35.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">5.&#9;Directive 95/46/EC of the European Parliament and of  \r\n\r\n the Council of 24 October 1995 on the protection of individuals with regard  \r\n\r\n to the processing of personal data and on the free movement of such data  \r\n\r\n (http://europa.eu.int/eur-lex/en/lif/dat/1995/en_395L0046.html). <I>Official  \r\n\r\n Journal of the European Communities</I> 1995;L281(28/11):31 50 (accessed 27  \r\n\r\n June 2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">6.&#9;International Conference on Harmonisation of  \r\n\r\n Technical Requirements for Registration of Pharmaceuticals for Human Use  \r\n\r\n (ICH). <I>Guideline for good clinical practice</I>  \r\n\r\n (http://www.ifpma.org/pdfifpma/e6.pdf). Brookwood Medical Publications,  \r\n\r\n Brookwood, Surrey, 1997 (accessed 27 June 2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">7.&#9;Colipa. <I>Guidelines for the evaluation of the  \r\n\r\n efficacy of cosmetic products</I>. Colipa, Rue du Congr&eacute;s, 5-7B,  \r\n\r\n B-1000 Brussels, Belgium, phone +32 (2) 2276610, fax +32 (2) 2276627.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">8.&#9;Serup J, Jemec GBE, ed. <I>Handbook of non-invasive  \r\n\r\n methods and the skin</I>. CRC Press, Boca Raton, FL, 1995.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">9.&#9;Serup J. EEMCO guidance for the assessment of dry  \r\n\r\n skin (xerosis) and ichthyosis: clinical scoring systems. <I>Skin Research and  \r\n\r\n Technology</I> 1995;1:109 14.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">10.&#9;Council of Europe. <I>Guidelines for Good  \r\n\r\n Manufacturing Practice of Cosmetic Products (GMPC)</I>. Council of Europe  \r\n\r\n Publishing, Council of Europe, F-67075 Strasbourg Cedex, 1995.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">11.&#9;British Standards Institution. <I>British Standard  \r\n\r\n recommendations for storage and exhibition of archival documents</I>. British  \r\n\r\n Standards Institution, 2 Park Street, London W1A 2BS, UK, phone +44 (071)  \r\n\r\n 6299000, 2000 (BS 5454:2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">12.&#9;US Food and Drug Administration. <I>Guidance for  \r\n\r\n industry: computerized systems used in clinical trials</I>  \r\n\r\n (http://www.fda.gov/ora/compliance_ref/bimo/ffinalcct.htm). US Food and Drug  \r\n\r\n Administration, Division of Compliance Policy, 1999 (accessed 27 June  \r\n\r\n 2000).</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">13.&#9;Spilker B, ed. <I>Guide to clinical trials</I>.  \r\n\r\n Raven Press, New York, 1991.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P></DIR>  \r\n\r\n</DIR>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Annex: terminology</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The terms used in this synopsis originate from scientific  \r\n\r\n use. The terms are arranged alphabetically and explained in the context of  \r\n\r\n documenting the efficacy of cosmetic products.</P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Adverse event or adverse product reaction</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">An event is any untoward biomedical occurrence in a  \r\n\r\n subject during a trial; a reaction is an untoward occurrence that is possibly  \r\n\r\n or likely related to the product.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Audit</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A systematic and independent examination of trial-related  \r\n\r\n activities and documents to determine whether the evaluated trial-related  \r\n\r\n activities were conducted and the data were recorded, analysed and accurately  \r\n\r\n reported according to the protocol, operating procedures, recommended  \r\n\r\n practices and applicable regulatory requirements.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Bias</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A point of view that prevents impartial judgement on  \r\n\r\n issues relating to that point of view. Trials attempt to control this through  \r\n\r\n double blinding. Bias is also any tendency for a value to deviate in one  \r\n\r\n direction from the true value. May be prevented by various techniques,  \r\n\r\n including randomization.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Blinding</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A procedure in which one or more parties to the trial are  \r\n\r\n kept unaware of the treatment assignment. Single-blinded usually refers to  \r\n\r\n the subjects being unaware of the assignment, and double-blinding usually  \r\n\r\n refers to the subjects, investigator, monitor and data analyst being unaware  \r\n\r\n of the assignment.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Case report form</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A printed or electronic document designed to record all  \r\n\r\n the information the protocol requires to be reported on each trial  \r\n\r\n subject.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Claim</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The product claim is the effect of the final product as  \r\n\r\n written in text on the physical product, any package insert, the package or  \r\n\r\n brochures or other written material prepared to inform the user. Claims may  \r\n\r\n also appear in other media such as advertisements, in the format of images  \r\n\r\n and in electronic versions. There may be a primary claim and a number of  \r\n\r\n secondary claims. Claims may also be multiple with no clear rank order.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Comparator product</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A reference treatment in a trial: a placebo, a marketed  \r\n\r\n product or another relevant comparator treatment.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Compliance</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Adherence to all trial-related requirements and the  \r\n\r\n applicable regulatory requirements.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Control(s)</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A reference test object or treatment (comparator product,  \r\n\r\n placebo or negative control) without effect or with documented action  \r\n\r\n (comparator product, active control or positive control). Control(s) may also  \r\n\r\n refer to reference subject(s) meeting various criteria for inclusion and  \r\n\r\n exclusion in the trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Documentation</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">All records in any form that describe or record the  \r\n\r\n methods, conduct and results of a trial, the factors affecting a trial and  \r\n\r\n the actions taken.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Endpoint</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">An indicator measured in a subject or biological sample to  \r\n\r\n assess efficacy (or safety or another trial objective). Endpoints may be  \r\n\r\n primary and pivotal or secondary and additional. To support claims, endpoints  \r\n\r\n in trials must be identical to or truly reflect the essence of the claim.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Ethics committee</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">An independent body (a review board or an institutional,  \r\n\r\n regional, national or supranational committee) comprising scientific  \r\n\r\n professionals and lay members responsible for ensuring the protection of the  \r\n\r\n rights, safety and well-being of human subjects involved in a trial and for  \r\n\r\n providing public assurance of that protection<I>.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n</I>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Fraud</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Deliberately exerted actions not described in the study  \r\n\r\n protocol or amendments changing a trial, its data and results in a way  \r\n\r\n serving a personal or partisan interest.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Informed consent</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A process by which a subject voluntarily confirms his or  \r\n\r\n her willingness to participate in a particular trial after having been  \r\n\r\n informed of all aspects of the trial that are relevant to the subject s  \r\n\r\n decision to participate. Informed consent is documented by means of a  \r\n\r\n written, signed and dated informed consent form.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Investigational product</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A product with declared composition being tested in a  \r\n\r\n trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Investigator or responsible scientist</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A person responsible for the conduct of a trial at the  \r\n\r\n trial site. If a trial is conducted by a team of individuals at the trial  \r\n\r\n site, the investigator is the responsible leader of the team.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Monitoring</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The act of overseeing the progress of a trial and of  \r\n\r\n ensuring that it is conducted, recorded and reported in accordance with the  \r\n\r\n protocol, operating procedures, described practices for proper conduct of  \r\n\r\n trials and applicable regulatory requirements.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Protocol</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A document that describes the objective(s), design,  \r\n\r\n methods, statistical considerations and organization of the trial. The  \r\n\r\n protocol also usually gives the background and rationale for the trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Quality assurance</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">All the planned and systematic actions that are  \r\n\r\n established to ensure that the trial is performed and the data generated,  \r\n\r\n documented (recorded) and reported properly according to described general  \r\n\r\n requirements.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Quality control</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">The operational techniques and activities undertaken  \r\n\r\n within the quality assurance system to verify that the requirements for  \r\n\r\n quality of the trial-related activities have been fulfilled in a particular  \r\n\r\n trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Sample size calculation</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">A statistical calculation of the number of subjects needed  \r\n\r\n in a specific trial to demonstrate or reject a statistically significant  \r\n\r\n difference between trial objectives, taking into account the precision of the  \r\n\r\n measuring system, the variation of the endpoint and the predefined  \r\n\r\n user-relevant change.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Selection</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Inclusion of subjects into and exclusion of subjects from  \r\n\r\n a trial according to a set of criteria defined in a study protocol.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Significance</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Means likelihood or importance. May refer to the  \r\n\r\n conclusion of a statistical calculation and be expressed as a probability  \r\n\r\n estimate (<I>P</I> value). May also refer to a real in-use situation. A  \r\n\r\n statistically significant difference is not automatically significant to the  \r\n\r\n user.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<B><P ALIGN=\"JUSTIFY\">Source data</P>  \r\n\r\n</B>  \r\n\r\n<P ALIGN=\"JUSTIFY\">All information in original records and certified copies  \r\n\r\n of original records of findings, observations or other activities in a trial  \r\n\r\n necessary to reconstruct and evaluate the trial. Source data are contained in  \r\n\r\n source documents, which are data and records on any medium.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Sponsor</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">An individual, company, institution or organization that  \r\n\r\n takes responsibility for initiating, managing and/or financing a trial.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<I><P ALIGN=\"JUSTIFY\">Standard operating procedure</P>  \r\n\r\n</I>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Detailed, written instructions to achieve uniformity of  \r\n\r\n the performance of a specific function.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">Spilker s classical textbook (13) explains some additional  \r\n\r\n terms and some basic principles of clinical trials.</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\"></P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">This synopsis was prepared for the Danish Environmental  \r\n\r\n Protection Agency, Ministry of Environment and Energy (Chemicals Division,  \r\n\r\n Wilders Plads Bygning O, DK-1403 Copenhagen K, Denmark) by J&oslash;rgen  \r\n\r\n Serup, M.D., Ph.D., Ingeborgvej 42, DK-2900 Hellerup, Denmark.</P>  \r\n\r\n<P>&nbsp;</P>  \r\n\r\n<P ALIGN=\"JUSTIFY\">&nbsp;</P>  \r\n\r\n</DIV><!-- End of \"Bilag 3\" -->  \r\n\r\n</DIV>",
    "isHistorical": true,
    "editorialNotes": [],
    "alternativeMedia": [],
    "ressort": "Miljøministeriet",
    "popularTitle": "Kosmetikvejledningen",
    "isReprint": false,
    "geografiskDaekningId": 0,
    "retsinfoKlassifikationId": 10,
    "caseHistoryReferenceGroup": [],
    "metadata": [
        {
            "displayName": "Offentliggørelsesdato",
            "displayValue": "23/02/2001"
        },
        {
            "displayName": "Accession",
            "displayValue": "C20000947460"
        },
        {
            "displayName": "Entydig dokumentidentifikation",
            "displayValue": "AL000631"
        },
        {
            "displayName": "Dato for førstegangsindlæggelse",
            "displayValue": "23/02/2001"
        },
        {
            "displayName": "Dato for indlæggelse",
            "displayValue": "09/03/2006"
        },
        {
            "displayName": "Dokumenttype",
            "displayValue": "Vejledning"
        },
        {
            "displayName": "Dokumentets rangering",
            "displayValue": "C "
        },
        {
            "displayName": "Forskriftens nummer",
            "displayValue": "9474"
        },
        {
            "displayName": "År for udstedelse",
            "displayValue": "2000"
        },
        {
            "displayName": "Dato for underskrift",
            "displayValue": "01/01/2000"
        },
        {
            "displayName": "Offentliggjort i (publiceringsmedie)",
            "displayValue": "Retsinformation"
        },
        {
            "displayName": "Administrerende myndighed",
            "displayValue": "Miljøstyrelsen"
        },
        {
            "displayName": "Ressortministeriets journalnummer",
            "displayValue": "Miljø- og Energimin.,<br />Miljøstyrelsen j.nr. 7041-0174"
        },
        {
            "displayName": "Stikord",
            "displayValue": "kosmetik, sikkerhedskrav"
        }
    ],
    "pdfLink": {
        "isPdfAvailable": false
    },
    "documentFobTagGroup": [],
    "hasFobTags": false
}